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ABSTRACT IN ENGLISH  
 
I studied the site-selectivity of Suzuki cross-coupling reactions of the bis(triflate) of 
naphthoates, coumarines, and isoflavones. In addition, the chemo-selectivity of Suzuki cross-
coupling reactions of naphthoates and quinolones containing bromide and triflate leaving 
groups were studied. In this context, prepared various arylated pharmacologically relevant 
heterocycles which are not readily available by other synthetic methods.    
 
ABSTRACT IN GERMAN  
 
Ich habe die Untersuchung der Regioselektivität von Suzuki-Miyaura 
Kreuzkupplungsreaktionen von Naphthalinen, Coumarinen, und Isoflavonen  untersucht. 
Weiterhin wurde  die Chemoselektivität von Suzuki-Reaktionen von Naphthalinen und 
Chinoline, die Bromid- und Triflatfluchtgruppen enthalten, untersucht. In diesem 
Zusammenhang gelang die Synthese arylierter Heterocyclen, die durch andere syntetische 
Methoden nicht hergestellt werden konnten. 
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1 Chapter One 
 
1.1 General Introduction 
The formation of carbon-carbon bonds is one of the most important themes in synthetic 
organic chemistry. The diversity and complexity of several natural products and biological 
active compounds have created the demand to establish and develop efficient synthetic 
approaches for constructing C-C bond. As a result for this demand, several conventional 
synthetic methods have been successfully developed for constructing C-C bond such as Aldol, 
the Diels-Alder, Michael reactions and the Claisen ester condensation.1a,b,c,d The first vital 
synthetic method was discovered by Victor Grignard for constructing carbon-carbon bonds by 
using organomagnesium reagents. Later, a diverse array of organometallic reagents were 
developed, which allow to overcome the limitations of the synthetic scope of Grignard 
reagents. For example, cross-coupling reactions of aryl halides have been realized by a variety 
of transition metal catalysts.1e As a result of these developments, the synthesis of a high 
number of complex molecules and natural products has become viable in the last decades. 
This important development in organometallic chemistry has led to award Y. Chauvin, R. H. 
Grubbs (ruthenium catalysts), and R. R. Schrock (molybdenum catalyst) with the Nobel Prize 
in 2005 for developing the olefin metathesis reaction, and in (2010) to Ei-ichi Negishi2, Akira 
Suzuki3 and Richard Heck for establishing economic and environmentally-friendly 
approaches for building carbon-carbon bonds.  
 
1.2 Palladium Chemistry 
During recent decades, the so-called palladium-(0)-catalyzed reactions have been developed 
in large areas of organic chemistry4, for example, in medical and pharmacological chemistry.5 
There are different types of palladium-catalyzed cross-coupling reactions6,7, which are known 
in organic synthesis, such as Suzuki, Heck, Stille, Sonogashira, Tsuji-Trost and Negishi 
reaction. Several groups have been working in the field of organometallic chemistry which 
developed many reagents based on the chemistry of palladium.  
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Scheme 1 Palladium-(0)-catalyzed cross-coupling reactions.  
 
 
The general mechanism of palladium-catalyzed cross-coupling reactions consists of three key 
steps7a,b, which involves;  
1. Oxidative addition, which includes formation of organometallic intermediate by  
addition of  aryl electrophile to palladium, such as aryl halides or triflates ( in this case 
the oxidation state of palladium-(0)-species  will be changed into palladium-(II)-
species).8,9  
2. Transmetallation process, where the organic moiety is transferred from a main group 
metal, such as Mg (Kumada reaction), Cu (Sonogashira reaction), Zn (Negishi 
reaction), B (Suzuki reaction) or Sn (Stille reaction), to a metal which is more 
electronegative, such as palladium to give a diorgano palladium complex.  
3. Reductive elimination, where the product is formed and the catalyst is regenerated 
again.10,11 (Scheme 2).  
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Scheme 2 General catalytic cycles for Suzuki-Miyaura reaction. 
 
1.3 Palladium-Catalyzed Suzuki-Miyaura Reaction 
The coupling of aryl halides with organoboronic acids is one of the most important palladium-
catalyzed cross-coupling reactions for both academic and industrial applications. This reaction 
may be defined as a reaction between aryl and vinyl-boronic acid with an aryl or vinyl-halide 
catalyzed by a Palladium-(0)-complex.12 
 
                     
Scheme 3 Palladium-Catalyzed Suzuki coupling. 
This reaction is widely used to synthesize poly-olefins, styrenes, and substituted biphenyls 
and the first work for this reaction was published in 1979 by Akira Suzuki and coworkers.13 
The organboranes and boronic acid in this reaction are very powerful partners. They are 
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commercially available, easy to handle, and relatively tolerant to air and to another functional 
groups. The main advantages of this reaction are the low temperature, low pressure, high 
yield, and the nontoxic by-products. Moreover, boron compounds are generally non-toxic. 
Consequently, all of these mild conditions make this reaction very interesting in the 
pharmaceutical and chemical industry.14 
 
 
1.4 Applications of Suzuki  Coupling Reactions 
The palladium-catalyzed cross-coupling reactions are important for the pharmacology and the 
chemical industry, and also in a big area for the synthesis of many important natural products. 
Thus, the palladium-catalyzed cross-coupling reactions are suitable for wide applications. In 
the following I present some examples for the use of palladium-catalyzed cross coupling 
reactions. The Suzuki reaction was used for preparing the antiviral brominated indole alkaloid 
dragmacidin-F.15 
 
                                        
Scheme 4 Synthesis of dragamacidin F via palladium-catalyzed Suzuki reaction.  
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Another application for the Suzuki reaction is the synthesis of the anti-cancer agent (+)-
dynemicin A (Scheme 5).16 
 
Scheme 5 Synthesis of (+)-dynemicin A via palladium-catalyzed Suzuki reaction.  
 
In the chemical industry, the Suzuki reaction could be used for the synthesis of industrial 
products, such as the drug Boscalid.17 
                                                      
Scheme 6 Synthesis of Boscalid via palladium-catalyzed Suzuki reaction.  
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1.5 Heck reaction 
Heck reaction is considered one of the most powerful synthetic tool which includes formation 
of C-C bond from coupling inactive C-H alkene bonds and (organ halides or triflates) by 
using palladium as a catalyst and in presence of a base (Scheme 7).17c 
 
 
Scheme 7 Palladium catalyzed Heck coupling reaction. 
 
 
1.6 Applications of Heck Coupling Reaction 
The Heck-reaction is one of the most important palladium-catalyzed cross-coupling reactions, 
which could be used for the synthesis of natural products, such as morphine.18  
 
 
Scheme 8 Synthesis of morphine via palladium-catalyzed Heck reaction. 
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The Heck reaction has been used also in the chemical industry for the synthesis of several 
new products, such as fine chemicals19 as shown in Scheme 9. 
 
                                   
Scheme 9 Synthesis of cyclotene via palladium-catalyzed Heck reaction.  
 
 
In the last years Prof. Langer’s group has extensively studied selective Suzuki-Miyaura cross-
coupling reactions preparing some unsymmetrical arylated pharmacologically relevant 
compounds. For example, the site-selective Suzuki coupling reaction of indole A was found to 
be in favor of the 2-position. This can be explained according to the sufficient difference in 
the electronic character of C-2 and C-3.19a Also, 2,3-dibromoindenone B gives an excellent 
site-selectivity, where the first attack occurred at position 319b (Scheme 10).  
 
 Scheme 10 Site-selectivity of A and B. 
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Furthermore, the following reactions show examples of site-selective Suzuki coupling 
reactions. For example, the reactions of the bis(triflate) of 5,7-dihydroxyflavone C and of the 
bis(triflate) of 5,7-dihydroxycoumarine D proceed favorably at the 7-position.19c,19d In both 
cases, the reason of the site-selectivity at position 7 in the coumarin and the flavone core 
structure can be explained by steric effects. The chemo-selective Suzuki coupling reaction of 
5,7-dibromo-8-(trifluoromethanesulfonyloxy)quinoline, containing bromide groups in the 
presence of a triflate, proceeds favorably at the 5-position E19e, because of the more electron 
deficient and sterically less hindered  character of that particular position (Scheme 11). 
 
 
Scheme 11 Site-selectivity of Suzuki reactions of C and D and of the chemo-selectivity of the 
reactions of E.  
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 CHAPTER TWO 
 
2    Synthesis of arylated naphthoates by site-selective Suzuki-Miyaura cross-coupling 
reactions of the bis(triflate) of methyl 3,7-dihydroxy-2-naphthoate 
     
2.1 Introduction 
Substituted naphthalenes are important lead structures in medicinal chemistry.20 They also act 
as intermediates in the synthesis of organic dyes and surfactants and as supporting agents in 
polymer industry.21 Naphthalenes derivatives exhibit a broad range of pharmacological 
activities, such as antimicrobial activity22 and activity as antibody inhibitors.23 Naphthalenes 
derivatives are found in a number of natural products. Examples include guieranone A which 
shows potent antifungal activity against Cladosporium cucumerinum (Figure 1).24 
Michellamine A, isolated from Ancistrocladus korupensis, has attracted the scientific 
community primarily because of its interesting binaphthyl structure and its antimalaria and 
anti-HIV activity.25,26 In contrast, 5-(6-hydroxynaphth-2-yl)benzene-1,3-diol was found to be 
very active against human breast cancer cell line B. Konzik et al. reported that aryl 
substituents of naphthalenes have a strong influence on their fungistatic activity.27 Therefore, 
arylated naphthalenes are of considerable pharmacological relevance.  
Many methods have been used for the preparation of substituted naphthalenes. For example, 
2-substituted naphthalenes were prepared by application of the Baylis–Hillman reaction,28 or 
by irradiation of 2-allylacylbenzenes in DMF.29 Other  methods include transition-metal-
catalyzed  [2+2+2] alkyne cyclizations,30 Lewis acid catalyzed cyclizations of carbonyl 
compounds with alkynes and [4+2] cycloadditons.31 An alternative approach relies on the 
functionalization of naphthalenes by palladium catalyzed cross-coupling reactions. Recently, 
Prof. Langer‘s group has reported the synthesis of arylated naphthalene by chemo- and site-
selective Suzuki-Miyaura reactions of naphthalene derivatives.32 Herein, I report what is, to 
the best of my knowledge, the first site-selective Suzuki-Miyaura cross-coupling reactions of 
the bis(triflate) of methyl 3,7-dihydroxy-2-naphthoate. 
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Figure 1 Pharmacologically important naphthalene derivatives. 
 
 
2.2 Results and discussion  
Commercially available 3,7-dihydroxy-2-naphthoic acid (1) was transformed into methyl 3,7-
dihydroxy-2-naphthoate (2) which was converted to bis(triflate) 3 in high yield (Scheme 12). 
 
Scheme 12 Synthesis of 3. Conditions: i, 1 (1.0 equiv.), Me2SO4 (2.2 equiv.), DIPEA (1.1 
equiv.), DMF, 85 °C, 1 h; ii, 1) 2 (1.0 equiv.), pyridine (4.0 equiv.), CH2Cl2, -78 C, 10 min; 
2) Tf2O (2.4 equiv.), -78 → 0 C, 4 h. 
  
   
The Suzuki-Miyaura reaction of 3 with arylboronic acids 4a-i (1.2 equiv.), in the presence of 
Pd(PPh3)4 (3 mol-%) and K3PO4 (1,5 equiv.) (THF, 20 °C, 9 h), afforded the 7-aryl-3-
(trifluoromethanesulfonyloxy)-2-naphthoates 5a-i in 70-85% yields (Scheme 13, Table 1). 
The reactions proceeded with very good site-selectivity in favor of position 6.  
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During the optimization, it proved to be important to carry out the reactions at 20 °C. Higher 
temperatures resulted in the formation of significant amounts of diarylated products. Very 
good yields were obtained for products derived from both electron poor and rich arylboronic 
acids. The structure of 5e was independently confirmed by X-ray crystal structure analysis 
(Figure 2). 
 
 
Scheme 13 Synthesis of 5a-i. Conditions: i, 3 (1.0 equiv.), 4a-i (1.2 equiv.), Pd(PPh3)4 (3 mol-
%), K3PO4 (1,5 equiv.), THF, 20 °C, 9 h. 
 
 
Table 1 Synthesis of 5a-i 
4   5 Ar %(5)a 
a   a 3,5-MeC6H3 70 
b   b 3-MeC6H4 77 
c   c 4-ClC6H4 80 
d  d 4-EtC6H4 84 
e   e 4-(MeO)C6H4 83 
f   f 4-MeC6H4 78 
g  g 4-(EtO)C6H4 82 
h   h 3-(MeO)C6H4 85 
i   i 3-FC6H4 82 
   a Yields of isolated products 
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Figure 2 X-ray crystal structure of 5e. 
 
 
The one-pot reaction of 3 with two different arylboronic acids (sequential addition of the 
arylboronic acid) afforded 3,7-diaryl-2-naphthoate 6 in 45% yield . The reaction was carried 
out at 20 °C for the first step (to avoid double coupling) and at 105 °C in the second step. An 
additional amount of catalyst and base had to be added together with the second arylboronic 
acid. 
 
                   
 
Scheme 14 Synthesis of 7. Conditions: i, 1) 3 (1.0 equiv.), 4-(MeO)C6H4B(OH)2 (1.0 equiv.), 
K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), THF, 20 °C, 9 h; 2) 4-MeC6H4B(OH)2 (1.0 equiv.), 
K3PO4 (1.5 equiv.), Pd(PPh3)4  (3 mol-%), 1,4-dioxane, 105 °C, 8 h.  
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Palladium catalyzed cross-coupling reactions usually occur at the electronically more 
deficient and sterically less hindered position.33,34 Prof. Langer‘s group has previously 
reported that Suzuki-Miyaura reactions of the bis(triflate) of phenyl 1,4-dihydroxy-2-
naphthoate proceed site-selectively at the more electron deficient, sterically more  hindered 
position 1 located next to the ester group. Also Prof. Langer‘s group has reported that Suzuki-
Miyaura reactions of the bis(triflate) of ethyl 3,5-dihydroxy-2-naphthoate (3.1a) proceed site-
selectively at the more electron deficient, sterically more hindered position 3 located next to 
the ester group.35 The selectivity was explained by the electron-withdrawing effect of the ester 
group and by a catalyst-direting effect of the ester group (chelation control). In case of the 
bis(triflate) of methyl 3,7-dihydroxy-2-naphthoate (3), the reactions proceed with very good 
site-selectivity in favour of the less electron deficient, sterically less hindered position 7. 
Therefore, the results are, on the first glance, in contrast to my previous results on substrate 
3.1a. However, the findings might be explained as follows: Position 7 of substrate 3 is less 
sterically hindered than position 5 of substrate 3.1a, due to the steric effect of the annulated 
ring (hydrogen atom at position 1). Therefore, in case of 3, the easy steric accessibility of 
position 7 seems to overrule the electron deficient character of position 3. In contrast, this is 
not possible for substrate 3.1a, because of the considerable steric demand of position 5. 
                      
 
Scheme 15 Site-selectivity of Suzuki–Miyaura reactions of 3 and 3.1a. 
  
2.3 Conclusion 
In conclusion, I have reported site-selective Suzuki-Miyaura reactions of the bis(triflate) of 
methyl 3,7-dihydroxy-2-naphthoate. These reactions provide a convenient approach to 
arylated naphthalene which are not readily available by other methods. 
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CHAPTER THREE 
 
3   Synthesis of arylated naphthoates by chemo-selective Suzuki-Miyaura cross- coupling 
reactions of methyl 4-bromo-3-(trifluoromethanesulfonyloxy)-2-naphthoate 
 
3.1 Introduction 
Naphthalenes derivatives exhibit a broad range of pharmacological activities, occur in many 
natural products, for example, Azinomycin A and B (Figure 3) were isolated from 
Streptomyces exhibit promising activities against leukemia,  Ehrlich carcinoma, Lewis lung 
carcinoma and Meth A fibrosarcoma.36 Substituted 2-naphthoates represent an important 
subgroup of naphthalene which show a wide range of pharmacological properties, such as 
cancerostatic activity.37 Several synthetic methods such as Baylis–Hillman reaction, 
transition-metal-catalyzed [2+2+2] alkyne cyclizations, Lewis acid catalyzed cyclizations and 
[4+2] cycloadditons have been developed for synthesizing substituted naphthalenes.38 
Recently, Prof. Langer’s group has reported the synthesis of arylated 2-naphthoates by site-
selective Suzuki–Miyaura reactions of bis(triflates) of dihydroxy-2-naphthoates.39 Prof. 
Langer’s group has started a program studying Suzuki–Miyaura reactions of several substrates 
containing a triflate and a bromide leaving group.40 These compounds generally reacted first 
at the bromide position. This was in agreement with earlier reports which showed that, in case 
of Suzuki–Miyaura reactions, aryl bromides are generally more reactive than aryl triflates, 
because of the stability of the boron–bromine bond formed during the reaction.41 As a part 
from the program, I studied the influence of some parameters, such as the structure of the 
substrate, on the chemo-selectivity Br/OTf. Herein, I report what is, to the best of my 
knowledge, the first Suzuki–Miyaura reactions of methyl 4-bromo-3-
(trifluoromethylsulfonyloxy)-2-naphthoate. These reactions proceed with very good 
chemoselectivity in favor of the triflate rather than the bromide group. The change of the 
chemoselectivity from Br to OTf can be explained by additive electronic ortho effects. 
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Figure 3 Azinomycin A X=CH2, Azinomycin B X=CHCHO. 
 
 
3.2 Results and discussion 
The DIPEA mediated reaction of 4-bromo-3-hydroxy-2-naphthoic acid (7) with dimethyl 
sulfate afforded methyl 4-bromo-3-hydroxy-2-naphthoate (8) which was transformed into 
methyl 4-bromo-3-(trifluoromethylsulfonyloxy)-2-naphthoate (9) by reaction with triflic 
anhydride (Scheme 16).  
  
 
Scheme 16 Synthesis of 9. Conditions: i, 7 (1.0 equiv), Me2SO4 (2.2 equiv), DIPEA 
(1.1 equiv), DMF, 85 °C, 1 h; (ii) 8 (1.0 equiv), pyridine (4.0 equiv), CH2Cl2, Tf2O 
(2.4 equiv), 50 °C, 20 min. 
 
 
The Suzuki–Miyaura reaction of 9 with arylboronic acids 4b–g, j (2.4 equiv) afforded methyl 
3,4-diaryl-2-naphthoates 10a–g in 69–93% yield (scheme 17)  and  both electron-poor and 
electron-rich arylboronic acids were successfully employed, but the yields of the products 
derived from the (more nucleophilic) electron-rich arylboronic acids were higher (except 
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for 10a). Very good yields were obtained under standard conditions, using 
Pd(PPh3)4 (6 mol %) as the catalyst, K2CO3 (2M, 2 mL) as the base, and 1,4-dioxane as the 
solvent (120 °C, 6 h). The use of 2-methylphenylboronic acid afforded the desired product 
which, however, could not be isolated in pure form (difficult chromatographic purification 
due to formation of side-products). 
 
 
 
Scheme 17 Synthesis of 10a-g. Conditions: i, 9 (1.0 equiv), 4b–g, j (2.4 equiv), 
Pd(PPh3)4 (6 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 120 °C, 6 h. 
 
 
Table 2 Synthesis of 10a-g 
4 10 Ar %(10)a 
b a 3-MeC6H4 72 
c b 4-ClC6H4 69 
d c 4-EtC6H4 81 
e d 4-(MeO)C6H4 86 
f e 4-MeC6H4 78 
g f 4-(EtO)C6H4 93 
j g 4-(CF3)C6H4 73 
a Yield of isolated products 
 
 
The Suzuki–Miyaura reaction of 9 with 1.0 equiv of arylboronic acids 4b–f afforded 3-aryl-4-
bromo-2-naphthoates 11a–e in 76–92% yield and the reactions proceeded with very good 
chemoselectivity in favor of the triflate group. During the optimization, it proved to be 
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important to use exactly 1.0 equiv of the arylboronic acid and to carry out the reaction at 
60 °C instead of 120 °C to avoid double coupling. Both electron-poor and electron-rich aryl 
boronic acids were successfully employed. The yields of the products derived from electron- 
rich arylboronic acids were again higher. The structures of the products were easily confirmed 
by the fact that, in the 13C NMR spectra, the characteristic quartet of the CF3 group 
disappeared. The structure of 11d was independently confirmed by X-ray crystal structure 
analysis (Figure 4). 
 
 
 
Scheme 18 Synthesis of 11a-e. Conditions: i, 9 (1.0 equiv), 4b–f (1.0 equiv), 
Pd(PPh3)4 (3 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 60 °C, 9 h. 
 
 
Table 3 Synthesis of 11a-e 
 
 
 
 
 
 
 
 
 
 
aYields of isolated 
 
 
 
 
 
4   11 Ar % (11)a 
b   a 3-MeC6H4 83 
c    b 4-ClC6H4 76 
d   c 4-EtC6H4 88 
e   d 4-(MeO)C6H4 92 
f   e 4-MeC6H4                79 
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Figure 4 X-ray crystal structure of 11d. 
 
 
The one-pot reaction of 9 with two different arylboronic acids (sequential addition) afforded 
the methyl 3,4-diaryl-2-naphthoates 12a–c, containing two different aryl groups, in 71–86% 
yield  and both electron-poor and electron-rich arylboronic acids were successfully employed. 
The best yield was obtained for product 12b derived from two electron-rich arylboronic acids. 
The lowest yield was obtained for product 12c where an electron-poor arylboronic acid was 
employed in the first step. 
 
 
Scheme 19 Synthesis of 12a–c. Conditions: i,(1) 9 (1.0 equiv), Ar1B(OH),  
Pd(PPh3)4 (3 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 60 °C, 9 h; (2) Ar
2B(OH) (1.2 equiv), 
Pd(PPh3)4 (6 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 120 °C, 6 h. 
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Table 4 Synthesis of 12a-c 
4 12 Ar1 Ar2 % (12)a 
d, j a 4-EtC6H4 4-(CF3)C6H4 79 
f, e b 4-MeC6H4 4-(MeO)C6H4 86 
c, d c 4-ClC6H4 4-EtC6H4 71 
aYields of isolated Product.  
 
 
3.3 Conclusion 
In conclusion, I have reported that Suzuki–Miyaura reactions of methyl 4-bromo-3-
(trifluoromethylsulfonyloxy)-2-naphthoate (9) proceeded by chemoselective attack to carbon 
atom C-3 attached to the triflate group. In contrast, Prof. Langer‘s group reported earlier that 
Suzuki–Miyaura reactions of 2-acetyl-4-bromo-1-(trifluorosulfonyloxy)naphthalene (9.1a) 
proceeded by chemoselective attack to carbon atom C-4 attached to the bromine atom.41a 
 
 
Scheme 20 Chemoselectivity of Suzuki–Miyaura reactions of 9 and 9.1a. 
 
  
It was mentioned above that, in the case of Suzuki–Miyaura reactions, aryl bromides are 
usually more reactive than aryl triflates. It is known that palladium catalyzed cross-coupling 
reactions proceed selectively in favor of the sterically less hindered and electronically more 
deficient position.42, 43 
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In addition, a carbonyl group can act as a catalyst-directing group (by chelation of the oxygen 
lone pairs to the metal). Carbon atoms C-3 and C-1 of substrates 9 and 9.1a, both attached to a 
triflate group, are more electron deficient than position C-4 of both substrates, because of the 
neighboring ester group, respectively. On the other hand, the ester carbonyl group can more 
efficiently chelate to the catalyst, due to the π-donating effect of the methoxy oxygen atom. 
Therefore, I believe that the chemoselectivity of the Suzuki–Miyaura reactions of 9 might be 
explained by additive electronic ortho effects, while the selectivity in case of 9.1a is a result 
of steric effects.  
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CHAPTR FOUR 
 
4    Synthesis of arylated coumarins by site-selective Suzuki-Miyaura cross-coupling    
reactions of the bis(triflate) of 4,7-dihydroxycoumarin  
 
4.1 Introduction 
Neoflavones (4-arylcoumarins) are of considerable pharmacological relevance and occur in 
several natural products and synthetic drugs.44 Natural and synthetic neoflavones have been 
reported to exhibit various kinds of pharmacological activities, such as anticancer,45 
antimalarial,46 antibacterial,47 antiprotozoal,48 antivirus,49 antidiabetic,50 cytotoxic,51 and anti-
inflammatory activity.52 Merck developed a 7-substituted 4-arylcoumarin as a 5-lipoxygenase 
inhibitor for the treatment of inflammatory diseases such as asthma, chronic obstructive 
pulmonary disease and atherosclerosis (Figure 5).53  As a result of the promising biological 
and pharmacological activities of neoflavones, several strategies have been developed for the 
construction of the 4-arylcoumarin framework. Classically, neoflavones have been 
synthesized using the Pechmann, Perkin, Ponndorf, Houben-Hösch and Knoevenagel 
reactions.54 In recent years, transition metal catalyzed reactions have emerged as vital 
synthetic tools for the preparation of pharmacologically relevant heterocycles. Two synthetic 
strategies have been developed for the assembly of the neoflavone framework: the first one 
involves the formation of the pyrone ring by hydroarylation of alkynes,55 or by reaction of the 
alkenyl C-H bond with carbon dioxide.55 The second one relies on cross-coupling reactions of 
position 4 of activated coumarins with organometallic reagents.57  
In recent years, site-selective cross coupling reactions of bis(halides) or bis(triflates) have 
been developed as a promising synthetic tool.58 In this context, palladium catalyzed cross-
coupling reactions of coumarin derivatives have also been reported.59 Herein, I report what is, 
to the best of my knowledge, the first Suzuki-Miyaura coupling reaction of the bis(triflate) of 
4,7-dihydroxycoumarin. The reactions, which proceed with excellent regioselectivity in favor 
of position 4, provide a convenient approach to various arylated coumarin derivatives which 
are not readily available by other methods. 
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Figure 5 A 5-lipoxygenase inhibitor developed by Merck. 
 
 
4.2 Results and discussion 
The reaction of 4,7-dihydroxycoumarin (13) with triflic anhydride gave bis(triflate) (Scheme 
21). 
 
                         
Scheme 21 Synthesis of 14. Conditions: i, 13 (1.0 equiv.), pyridine (4.0 equiv.), CH2Cl2, Tf2O 
(2.4 equiv.), 50°C, 4 h. 
 
 
The Suzuki–Miyaura reaction of 14 with arylboronic acids 4a, e, g, k, l (2.4 equiv) afforded 
4,7-diarylcoumarins 15a-e in 66-81% yield (Scheme 22, Table 5). Both electron rich and poor 
arylboronic acids were successfully employed. 
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Scheme 22 Synthesis of 15a-e. Conditions: i, 14 (1.0 equiv.), 4a, e, g, k, l (2.4 equiv.), 
Pd(PPh3)4 (6 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 110 °C, 8 h. 
  
 
Table 5 Synthesis of 15a-e 
 
aYields of isolated product. 
 
 
The Suzuki–Miyaura reaction of 14 with one equivalent of arylboronic acids afforded the 4-
aryl-7-(trifluormethanesulfonyloxy)-coumarins 16a-h in 64-82 % yield (Scheme 23, Table 6). 
The reactions proceeded by site-selectivity attack onto 4-position. During the optimization, it 
proved to be important to carry out the reaction at lower temperature (65 °C) as compared to 
the synthesis of the diarylated coumarins. In addition, the employment of toluene (instead of 
1,4-dioxane) proved to be important to avoid formation of diarylated products. Again, both 
electron rich and poor arylboronic acids gave good yields. The structure of 16a was 
independently confirmed by X-ray crystal structure analyses (Figure 6). 
 
 
 
 
4   15 Ar % (15)a 
a   a 3,5-MeC6H3 81 
e   b 4-(MeO)C6H4 68 
g   c 4-(EtO)C6H4 66 
k  d C6H5 79 
l   e 3,5-(MeO)C6H3                69
Results & Discussion 
24 
 
               
Scheme 23 Synthesis of 16a-h. Conditions: i, 14 (1.0 equiv.), 4a, d-g, i, m, n (1.0 equiv.), 
Pd(PPh3)4 (3 mol %), K2CO3 (2M, 2 mL), toluene (3 mL), 65 °C, 6 h. 
 
 
Table 6 Synthesis of 16a-h 
4 16 Ar % (16)a 
a a 3,5-MeC6H3 82  
d b 4-EtC6H4 73 
e c 4-(MeO)C6H4 71 
f d 4-MeC6H4                    70  
g e 4-(EtO)C6H4 78 
i f 3-FC6H4 64 
m g 4-(OCF3)C6H4     65 
n h 2,3,4-(MeO)C6H2         67 
a Yield of isolated products 
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 Figure 6 X-ray crystal structure of 16a. 
 
 
The one-pot reaction of 14 with two different arylboronic acids (sequential addition) afforded 
the diarylated coumarin 17 in 84 % yield (Scheme 24). A fresh portion of the catalyst and of 
solvent (1,4-dioxane) had to be added to the reaction mixture in the second step in order to 
obtain a good yield of diarylated coumarin 17. 
 
                      
Scheme 24 Synthesis of 17. Conditions: i, 1) 14 (1.0 equiv.), 4-(MeO)C6H4B(OH)2 (1.0 
equiv.), Pd(PPh3)4 (3 mol %), K2CO3 (2M, 2 mL), toluene, 65 °C, 6 h.; 2) 4-MeC6H4B(OH)2 
(1.2 equiv.), Pd(PPh3)4 (6 mol %), K2CO3 (2M, 2 mL), 1,4-dioxane, 110 °C, 6 h. 
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4.3 Conclusion 
 In conclusion, I have reported the first Suzuki–Miyaura reactions of 4,7-
bis(trifluoromethylsulfonyloxy)coumarin. These reactions provide a convenient access to a 
variety of arylated coumarins.  The reactions proceeded with very good site-selectivity in 
favor of 4-position. Palladium catalyzed cross-coupling reactions of polyhalogenated 
substrates or of bis(triflates) usually proceed in favor of the sterically less hindered and 
electronically more deficient position. Position 4 is sterically more hindered than position 7, 
due to its location next to the annulated benzene ring. The selectivity can be explained by the 
highly electron deficient character of the 4-position of the coumarin moiety (electron-
withdrawing effect of the carbonyl group). 
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CHAPTER FIVE 
  
5    Synthesis of arylated quinolines by chemo-selective Suzuki-Miyaura cross-coupling 
reactions of 5-bromo-quinolin-8-yl-trifluoromethanesulfonate 
 
5.1 Introduction 
Arylated quinolines exhibit a wide range of pharmacological and biological activities, such as 
antivirus60, antimalarial, antitumor and P-selecting antagonism.61 They are also promising 
agents for the treatment of acromegaly62 and diabetic retinopathy.63 As a result of their 
therapeutic value, many synthetic approaches have recently been developed. The classic 
condensation-type approaches for the synthesis of arylated quinolines include the Skraup, 
Doebner-Miller, Friedländer, Combes, Pfitzinger and Povarov reactions.64 Cross-coupling 
reactions have become an efficient synthetic tool in the synthesis of arylated quinolines and 
quinolines as well.65 Also, new transition metal catalytic systems have been developed for 
construction of arylated quinoline frameworks such as, Rh(III)-catalyzed oxidative 
annulations of pyridines,66 Pd-catalyzed hetero-Diels-Alder reactions between imines and 
olefins,67 Ru(I)-catalyzed coupling cyclizations of N-aryl imidoyl chloride with alkynes,68 
Ru(II)- catalyzed Friedländer annulations69 and Pd-catalyzed regioselective hydroarylations of 
α-(2-aminoaryl)-α,β-alkynones with organoboron derivatives.70 Recent progress in Pd-
catalyzed selective cross-coupling reactions have led to develop various protocols in the 
synthesis of some drugs and drug candidates in pharmaceutical industry.71 For example, a 
diverse range of 4-alkoxy-3,6-diarylquinolines as drug candidates have been synthesized by 
chemo-selective Suzuki reactions as the key step. The products exhibit potent and selective 
agonism of the somatostatin receptor subtype 2 (sst2) (Figure 7).
72 
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Figure 7 Selective Pd-catalyzed synthesis of 4-alkoxy-3,6-diarylquinolines (sst2), agonists 
protocol developed by Merck. 
 
 
Previously, various regioselective Suzuki-Miyaura cross-reactions of dihalogenated pyridines 
and quinolines have been reported.73,74 Reactions of mixed triflates and halides are more rare. 
Some years ago, Prof. Langer’s group has reported reactions of quinolones containing a 
triflate and two bromine atoms. Prof. Langer’s group also reported chemoselective 
transformations of naphthalene derivatives containing triflate and bromide groups.75 In 
chapter 3 of this work such reactions are also described. Herein, I report what is, to the best of 
my knowledge, the first chemo-selective Suzuki-Miyaura reactions of 5-bromoquinolin-8-yl 
trifluoromethanesulfonate.   
 
5.2 Results and discussion  
Commercially available 5-bromo-8-hydroxyquinoline was converted to 5-bromoquinolin-8-yl 
trifluoromethanesulfonate 19 in high yield (Scheme 25). 
  
                                            
Scheme 25 Synthesis of 19. Conditions: i, 18 (1.0 equiv.), pyridine (1.2 equiv.), (20 mL) 
CH2Cl2, Tf2O (1.2 equiv.), 50
 °C, 4 h. 
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The Suzuki-Miyaura reaction of 19 with arylboronic acids 4a, b, e, g (2.0 equiv.), in the 
presence of Pd(PPh3)4 (6 mol-%), K2CO3 (2 mL), 1,4-dioxane (3 mL), 110 °C, 10 h, gave 5,8-
bis(aryl)quinolines 20a-d in 68-81% yields  (Scheme 26, Table 7). The structure of compound 
20c was independently confirmed by x-ray crystallography (Figure 8).     
 
                                            
Scheme 26 Synthesis of 20a-d. Conditions: i, 19 (1.0 equiv.), 4a, b, e, g (2.0 equiv.), 
Pd(PPh3)4 (6 mol-%), K2CO3 (2 mL), 1,4-dioxane (3 mL), 110 °C, 10 h. 
 
 
Table 7 Synthesis of 20a-d 
4 20      Ar %(20)a 
a   a 3,5-MeC6H3 81 
b  b 3-MeC6H4 77 
e   c   4-(MeO)C6H4            68
g  d 4-(EtO)C6H4 72 
a Yields of isolated products 
 
 
 
 
 
 
 
Figure 8 X-ray crystal structure of 20c. 
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The Suzuki-Miyaura reaction of 19 with arylboronic acids 4a, c-g, o, p (1.0 equiv.), in the 
presence of Pd(PPh3)4 (3 mol-%), K3PO4 (1.0 equiv.), toluene (3 mL), 85 °C, 9 h, afforded 5-
arylquinolin-8-yl trifluoromethanesulfonates 21a-h in 60-84% yields (Scheme 27, Table 8). 
The reactions proceeded with very good chemoselectivity in favor of position 5. During the 
optimization, it proved to be important to use exactly one equivalent of the arylboronic acid to 
carry out the reaction at lower temperature (85 °C) than the double-coupling. Very good 
yields were obtained for products derived from both electron poor and rich arylboronic acids. 
The structure of 21a was confirmed by 2D NMR correlation experiments (NOESY and 
COSY)   (Figure 9). 
 
                                          
Scheme 27 Synthesis of 21a-h. Conditions: i, 19 (1.0 equiv.), 4a, c-g, o, p (1.0 equiv.), 
Pd(PPh3)4 (3 mol-%), K3PO4 (1.0 equiv.), toluene (3 mL), 85 °C, 9 h. 
 
 
Table 8 Synthesis of 21a-h 
4 21 Ar %(21)a 
a a 3,5-MeC6H3 76 
c b 4-ClC6H4 60 
d c 4-EtC6H4 75 
e d 4-(MeO)C6H4 84 
f e 4-MeC6H4 81 
g f 4-(EtO)C6H4      69 
o g 4-FC6H4             63 
p h 2-(MeO)C6H4 79 
a Yields of isolated product 
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Figure 9 2D NMR correlation experiments of compound 21a (NOESY: green arrows; COSY: 
blue arrows).  
 
The one-pot reaction of 19 with two different arylboronic acids (sequential addition of the 
arylboronic acids) afforded 5,8-diarylquinoline 22 in 76% yield (Scheme 28). The reaction 
was carried out at 85 °C for the first step (to avoid double coupling) and at 110 °C in the 
second step (to ensure a complete reaction). An additional amount of catalyst and base had to 
be added together with the second arylboronic acid. In addition, 1,4-dioxane (3 mL) had to be 
added to complete the reaction, due to solubility reasons.  
 
                                        
Scheme 28 Synthesis of 22. Conditions: i, 1) 4-MeC6H4B(OH)2 (1.0 equiv.), Pd(PPh3)4 (3 
mol-%), K3PO4 (1.0 equiv.), toluene, 85 °C, 9 h.; 2) 4-(MeO)C6H4B(OH)2 (2.0 equiv.), 
Pd(PPh3)4 (6 mol-%), K3PO4 (1.0 equiv.), 1,4-dioxane, 110 °C, 10 h. 
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In general, aryl bromides undergo Suzuki-Miyaura reactions more rapidly than aryl triflates,76 
because of the stability of the borane-halide bond. However, other parameters influence the 
selectivity as well.76e The reactions of 19 proceed with very good chemoselectivity of the 
bromide group, despite the proximity of the triflate to the quinoline nitrogen which might 
exert a catalyst-directing effect based on participation of the nitrogen lone pairs. 
 
5.3 Conclusion 
In conclusion, I have reported chemoselective Suzuki-Miyaura reactions of 5-bromoquinolin-
8-yl trifluoromethanesulfonate. The reactions proceeded with very good chemoselectivity in 
favor of the bromide group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
33 
 
CHAPTER SIX  
 
6    Synthesis of arylated isoflavones by site-selective Suzuki-Miyaura cross-coupling 
reactions of the bis(triflate) of 5,7-dihydroxyisoflavone 
 
6.1 Introduction 
Isoflavones are heterocyclic compounds, which belong to flavonoids derivatives. The main 
body of isoflavone consists of a benzene and a ortho-pyrone moiety. Isoflavonoids are a 
subgroup of flavonoids mainly present in the species of Leguminosae (Figure 10). New 
syntheses of isoflavones have been developed in recent years. Syntheses rely on the 
cyclization of deoxybenzoin derivatives with suitable building blocks, using various reagents, 
such as ethoxalyl chloride77 or triethyl orthoformate.78 Furthermore, palladium catalyzed 
cross-coupling reactions have been used for the synthesis of isoflavones.79 Isoflavone 
derivatives show anticancer,80 and antibacterial,81 antimicrobial,82 and antiulcer activity.83 
Isoflavones also play a role for the reduction of cholesterol.84 Isoflavones also possess 
antioxidant activity,85 inhibition of cancer cell proliferation,86 anti-inflammatory activity,87 
and prevention of coronary heart diseases88 as well as osteoporosis.89  
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Figure 10 Species of Leguminosae. 
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6.2 Results and discussion 
Commercially available 5,7-dihydroxyisoflavone (23) was converted to 5,7-
bis(trifluoromethanesulfonyloxy)isoflavone (24) in high yield 89% (Scheme 29). 
 
                    
 Scheme 29 Synthesis of 24. Conditions:  i, 23 (1.0 equiv.), pyridine (4.0 equiv.) CH2Cl2, 
Tf2O (2.4 equiv.), 50 °C, 4 h. 
 
 
The Suzuki-Miyaura reaction of 24 with arylboronic acids 4a, d, f (2.0 equiv.), in the 
presence of Pd(PPh3)4 (6 mole%), K2CO3 (1.5 mL), 1,4-dioxane (3 mL), 110 °C, 10 h., gave 
the 5,7-diaryl isoflavones 25a-c in 76-87 % yields  (Scheme 30, Table 9). 
 
 
Scheme 30 Synthesis of 25a-c. Conditions: i, 24 (1.0 equiv.), 4a, d, f (2.0 equiv.), Pd(PPh3)4 
(6 mole%), K2CO3 (1.5 mL), 1,4-dioxane (3 mL), 110 °C, 10 h. 
 
 
 
 
 
 
 
  
Table 9 Synthesis of 25a-c 
4 25 Ar %(25)a 
a a 3,5-MeC6H3 87 
d b 4-EtC6H4 81 
f c 4-MeC6H4 76 
aYields of isolated product 
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 The Suzuki-Miyaura reaction of 24 with arylboronic acids 4a, d-f (1.0 equiv.), in the 
presence of Pd(PPh3)4 (3 mole%), K3PO4 (1.0 equiv.), THF (3 mL), 55 °C, 10 h, afforded the 
5-arylisoflavone-7-trifluoromethanesulfonates 26a-d in 73-82% yields (Scheme 31, Table 
10). The reactions proceeded with very good chemo-selectivity in favor of position 7. Very 
good yields were obtained for products derived from both electron poor and rich arylboronic 
acids. The structure of compound 26c, confirmed independently by x-ray (Figure 11).  
 
                   
Scheme 31 Synthesis of 26a-d. Conditions: i, 24 (1.0 equiv.), 4a, d-f (1.0 equiv.), Pd(PPh3)4 
(3 mole%), K3PO4 (1.0 equiv.), THF (3 mL), 55 °C, 10 h. 
 
 
 
 
 
 
 
 
 
 
Table 10 Synthesis of 26a-d 
4 26 Ar %(26)a 
a a 3,5-MeC6H3 73 
d  b 4-EtC6H4 79 
e  c 4-(MeO)C6H4 80 
f d 4-MeC6H4 82 
aYields of isolated product 
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Figure 11 X-ray crystal structure of 26c. 
 
 
6.3 Conclusion 
In conclusion, I have reported site-selectivity Suzuki-Miyaura reactions of bis (triflate) of 5,7-
dihydroxyisoflavone. The reactions proceeded with very good site-selectivity in favor of 5-
position. 
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7   EXPERMENTAL SECTION  
  
7.1 NMR Spectroscopy 
Burker AC 250, Burker ARX 300, Burker ARX 500. For NMR characterization the one-
dimensional 1H NMR; Proton-decoupled 13C NMR, and DEPT 135 spectra were collected. If 
necessary, other techniqes (NOESY, COSY, HMQC, and HMBC) were applied as well. All 
NMR spectra presented in this work were collechted in CDCl3 Solution. All chemical schift are 
given in ppm.References (1H NMR): TMS (γ= 0.00) or residual CHCl3 (γ= 7.26) were taken as 
internal standard.References (13C NMR): TMS (γ= 0.00) or residual CHCl3 (γ= 77.0) were 
taken as internal standard.Multiplicities are given as follows: s = singlet, d = doublet, t = triplet, 
q= quartet, m = multiplet, br = broad singlet.  More complex patterns are represented by 
combinations of the respective symbols.Td indicates a triplet of doublets with the larger 
coupling constant associated with the first symbol (here, triplet). 
 
7.2 Infraed Spectroscopy (IR) 
Nicolet 205 FT-IR, Nicolet Protégé 460 FT-IR. Peaks are given the following assignments: W 
= Weak, m = medium, s = strong, br = broad. 
 
7.3 Mass Spectroscopy (MS) 
AMD MS40, Varian MAT CH 7, MAT 731 (ET, 70 eV), Intecta AMD 402 (ET, 70 eV and 
Cl), Finnigan MAT 95 (Cl, 200 eV) 
 
7.4 High Resolution Mass Spectrometry (HRMS) 
Varian MAT 311, Intecta AMD 402. 
 
7.5 Melting Points 
Micro heating table HMK 67/1825 Kuestner (Büchi Apparatus). Leitz Labolux 12 pol with 
heating table Mettler FP 90. Melting Points are uncorrected.  
 
7.6 X-ray Structures 
Burker X8Apex diffractometer with CCD camera (Mo Ka, radiation and graphite 
monochromator, λ= 0.71073 Å). The space group is determined by the XPREA program and 
the structures were solved via the SHELX-97 program package. Refinements were carried out 
according to the minimum square error method. 
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7.7 Chromatographic Methods 
7.7.1 Thin Layer Chromatography (TLC) 
Merck Kiesslgel 60 F254 on aluminium foil from Macherey-Nagel. Detection was carried oht 
under UV light at 254 nm and 365 nm. As colourizing reagent the following mixtures were 
used: 1-2 100/ p-Anisaldehyde or vanillin, 10/100 glacial acetic, 5/100 sulphuric acid, 83-
84/100 methanol. 
 
7.7.2 Column Chromatography 
Column chromatography was performed with Merck Silica Gel 60 or Macherey-Nagel Silica 
Gel 60 (0,063-0.0200 mm, 70-320 mesh). The finer Merck Silica Gel 60 (0.040-0.063 mm, 230-
400 mesh) was chosen when appropriate. 
 
7.8 Equipment, Chemicals and work Technique 
All solvents for using were distilled by standard methods. The coupling reactions were carried 
out in pressure tubes or Schlenck flask under inert atmosphere (Argon 4.6), oxygen and 
humidity exclusion. All of the chemicals are standard, commercially available from Merck, 
Aldrich, Arcos, and others. The order of the characterized connections effected numerically, 
but does not correspond to the order in the main part of dissertation. 
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7.9 Procedures and Spectroscopic Data 
Methyl 3,7-dihydroxy-2-naphthoate (2) 
To a solution of 3,7-dihydroxy-2-naphthoic acid 1 (2.0 g, 9.8 
mmol) in DMF (30 mL), dimethyl sulfate (2.72 g, 21.56 mmol) 
and N,N-diisopropylethylamine (1.4 g, 10.78 mmol) were added. 
The reaction mixture was heated for 1 h at 85 °C. After cooling to 
room temperature, the mixture was poured into ice water. A white precipitate formed which 
was filtered off and the filtrate was concentrated in vacuo. The product 2 was isolated by column 
chromatography (flash silica gel, heptane/EtOAc) as a yellow solid (1.6 g, 77%); mp 101-102 
°C. 1H NMR (300 MHz, CDCl3): δ = 3.95 (s, 3H, OCH3), 4.79 (s, 1H, OH), 7.04-7.05 (m, 1H, 
ArH), 7.08 (dd, J = 2.4, 8.8 Hz, 1H, ArH), 7.20 (s, 1H, ArH), 7.55 (d, J = 8.9 Hz, 1H, ArH), 
8.25 (s, 1H, ArH), 10.19 (s, 1H, OH). 13C NMR (62.90 MHz, CDCl3):  = 52.5 (OCH3), 110.1, 
111.8 (CH), 114.6 (C), 121.6 (CH), 127.7 (C), 128.1, 130.3 (CH), 133.4, 151.7, 154.7 (C), 170.2 
(CO). IR (KBr, cm-1):  v = 3328 (m), 3038, 3003, 2953 (w), 1681 (m), 1651, 1633, 1609, 1576, 
1556 (w), 1531 (m), 1505, 1479, 1462 (w), 1441, 1392, 1345, 1263, 1214 (s), 1180, 1147, 1130, 
1072 (m), 1012, 969 (w), 944, 903, (w), 860 (s), 836, 812 (m), 783 (s), 746 (w), 716 (s), 665, 
620, 610 (w), 587, 550 (w). GC-MS (EI, 70 eV): m/z (%) = 218 ([M]+, 52), 187 (17), 186 (100), 
185 (10), 159 (10), 158 (80), 130 (45), 102 (20). HRMS (EI, 70 eV) calcd for C12H10O4 [M]
+: 
218.0579; found: 218.0599. 
 
Methyl 3,7-bis(trifluoromethylsulfonyloxy)-2-naphthoate (3) 
 To a CH2Cl2 solution (46 mL) of 2 (1.0 g, 4.6 mmol) was added 
pyridine (1.5 mL, 18.4 mmol) and the solution was stirred at 20 
°C for 10 min under argon atmosphere. Then Tf2O (1.8 mL, 11.0 
mmol) was added at –78 °C and the reaction mixture was allowed 
to warm to room temperature and was stirred for 14 h. The reaction mixture was filtered and 
the filtrate was concentrated in vacuo. The product 3 was isolated by column chromatography 
(flash silica gel, heptane/EtOAc) as a colourless solid (1.9 g, 87%); mp 75-77 oC. 1H NMR (300 
MHz, CDCl3): δ = 4.06 (s, 3H, OCH3), 7.47-7.70 (m, 1H, ArH), 7.85 (s, 1H, ArH), 7.94 (d, J 
= 2.3 Hz, 1H, ArH), 8.03 (d, J = 9.0 Hz, 1H, ArH), 8.72 (s, 1H, ArH). 13C NMR (62.90 MHz, 
CDCl3 = 52.99 (OCH3), 117.7 (q, JF,C = 320.2 Hz, CF3), 117.9 (q, JF,C = 320.8 Hz, CF3), 120.4, 
121.2, 123.6 (CH), 130.5 (C), 130.8 (CH), 131.8, 133.8 (C), 134.6 (CH), 145.5, 148.3 (C), 163.7 
(CO). IR (KBr, cm-1): v = 3070, 2963 (w), 1713 (s), 1678, 1633 (w), 1599 (m), 1502, 1461, 
1443 (w), 1426, 1398 (s), 1365, 1309 (m), 1276 (s), 1249 (m),1203, 1131, 1116, 1048 (s), 965 
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(w), 937, 909, 937, 909, 845, 813, 795 (s), 779, 766, 754, 739 (m), 697 (w), 676 (m), 650, 609, 
(s), 597, 582 (m), 565 (w). GC-MS (EI, 70 eV): m/z (%) = 482 ([M]+, 61), 451 (16), 350 (14), 
349 (100), 257 (24), 129 (17). HRMS (ESI-TOF/MS) calcd for C14H9F6O8S2 [M+H]
+: 
482.96375; found: 482.96348. 
 
General procedure for the synthesis of 5a-i 
A THF solution of 3 (0.145 mmol), K3PO4 (1.5 equiv), Pd(PPh3)4 (3 mol-%) and of arylboronic 
acid 4 (1.2 equiv.) was stirred at 20 °C for 9 h under argon atmosphere. To the reaction mixture 
were added H2O (20 mL) and CH2Cl2 (25 mL). The organic and the aqueous layers were 
separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers 
were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, heptane / EtOAc = 100:5). 
 
Methyl 7-(3,5-dimethylphenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5a) 
Starting with 3 (70 mg, 0.145 mmol), 4a (26 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol), and THF (4 mL), 5a was isolated as a white solid (45 
mg, 70%); mp 102-104 °C. 1H NMR (300 MHz, CDCl3): δ 
= 2.35 (s, 6H, 2CH3), 3.96 (s, 3H, OCH3), 7.01 (s, 1H, ArH), 
7.24 (br. s, 2H, ArH), 7.68-8.08 (m, 4H, ArH), 8.63 (s, 1H, ArH). 19F NMR (282.4 MHz, 
CDCl3): δ = -73.1. 13C NMR (75.5 MHz, CDCl3): δ = 20.4 (2CH3), 51.7 (OCH3), 117.8 (q, JC,F 
= 321.3 Hz, CF3), 119.8 (CH), 121.2 (C), 124.3, 125.2, 125.6, 128.1, 128.8 (CH), 130.7, 132.9 
(C), 134.0 (CH), 137.7, 138.7, 140.2, 143.6 (C), 164.4 (C=O). IR (KBr, cm-1): v = 3028, 3012, 
2958, 2920, 2851 (w), 1721 (s), 1632 (w), 1596 (m), 1462 (w), 1420 (s), 1364, 1319, 1303, 
1285, 1261, 1247 (w), 1198 (s), 1134, 1112, 1051, 1018, 946 (m). GC-MS (EI, 70eV): m/z (%) 
= 438 ([M]+, 44), 305 (100), 275 (15), 247 (39), 219 (20), 202 (24). HRMS (EI, 70 eV): m/z 
calcd. for C21H17O5F3S [M]
+: 438.07433; found: 438.07419. 
 
Methyl 7-(m-tolyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5b) 
Starting with 3 (70 mg, 0.145 mmol), 4b (24 mg, 0.174 mmol), 
Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 mmol), and 
THF (4 mL), 5b was isolated as a white solid (48 mg, 77%); mp 
152-154 °C. 1H NMR (300 MHz, CDCl3): δ = 2.35 (s, 3H, CH3), 
3.96 (s, 3H, OCH3), 7.00 (s, 1H, ArH), 7.18-7.24 (m, 3H, ArH), 
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7.68 (s, 1H, ArH), 7.87 (br. s, 2H, ArH), 8.10 (s, 1H, ArH), 8.63 (s, 1H, ArH). 19F NMR (282.4 
MHz, CDCl3): δ = -73.07. 13C NMR (75.5 MHz, CDCl3): δ = 21.4 (CH3), 52.7 (OCH3), 118.9 
(q, JC,F = 320.9 Hz, CF3), 119.8 (CH), 121.3 (C), 123.5, 125.6 (CH), 127.1 (C), 127.7 (CH), 
127.9 (2CH), 128.1, 128.6 (CH), 130.7, 133.0 (C), 134.0 (CH), 137.8, 138.7, 144.6 (C), 163.9 
(C=O). IR (KBr, cm-1): v = 3042, 3018, 2960, 2916 (w), 1721 (s), 1602, 1505, 1422, 1319, 
1287, 1258, 1201 (m), 1134, 1085 (w), 1013 (s), 955, 944 (w). GC-MS (EI, 70eV): m/z (%) = 
424 ([M]+, 57), 292 (19), 291 (100), 263 (10), 261 (15), 233 (48), 205 (23). HRMS (ESI-
TOF/MS): m/z calcd for C20H16O5F3S [M+H]
+: 425.05923; found: 425.05934. 
 
Methyl 7-(4-chlorophenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5c) 
 Starting with 3 (70 mg, 0.145 mmol), 4c (27 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol), and THF (4 mL), 5c was isolated as a white solid 
(52 mg, 80%); mp 98-100 °C. 1H NMR (300 MHz, 
CDCl3): δ = 3.95 (s, 3H, OCH3), 7.18-7.33 (m, 1H, ArH), 7.38 (d, J = 8.1 Hz, 2H, ArH), 7.55 
(d, J = 8.1 Hz, 2H, ArH), 7.69 (s, 1H, ArH), 7.76-7.90 (m, 1H, ArH), 8.04 (s, 1H, ArH), 8.62 
(s, 1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.1. 13C NMR (75.5 MHz, CDCl3): δ = 52.8 
(OCH3), 118.3 (q, JC,F = 320.9 Hz, CF3), 119.9 (CH), 121.8 (C), 125.6, 127.4, 127.6, 128.2, 
128.3 (CH), 130.6, 133.0, 133.4 (C), 133.9 (CH), 137.2, 138.7, 143.8 (C), 163.3 (C=O). IR 
(KBr, cm-1): v = 3033, 3000, 2956, 1723 (s), 1632, 1604, 1490 (m), 1420 (s), 1318, 1260, 1248 
(w), 1201 (s), 1131, 1091, 1050, 1011 (w), 963, 928 (m). GC-MS (EI, 70 eV ): m/z (%) = 446 
([M], 37Cl]+, 24),  444 ([M], 35Cl]+, 61),  410 (40), 329 (15), 311 (100), 270 (10). HRMS (ESI-
TOF): m/z calcd. for C19H13ClF3O5S ([M+H], 
35Cl)+: 445.01188; found: 445.01173; calcd for 
C19H13ClF3O5S ([M+H], 
37Cl)+: 447.00951; found 447.00954.  
 
Methyl 7-(4-ethylphenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5d) 
 Starting with 3 (70 mg, 0.145 mmol), 4d (26 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol), and THF (4 mL), 5d was isolated as a white solid 
(54 mg, 84%); mp 66-68 °C. 1H NMR (300 MHz, CDCl3): δ 
= 1.21 (t, J = 7.5 Hz, 3H, CH3), 2.66 (q, J = 7.5 Hz, 2H, 
CH2), 3.95 (s, 3H, OCH3), 7.27 (d, J = 8.1 Hz, 2H, ArH), 7.55 (d, J = 8.1 Hz, 2H, ArH), 7.68 
(s, 1H, ArH), 7.87 (br. s, 2H, ArH), 8.07 (s, 1H, ArH), 8.62 (s, 1H, ArH). 19F NMR (282.4 
MHz, CDCl3): δ = -73.05. 13C NMR (75.5 MHz, CDCl3): δ = 15.5 (CH3), 28.5 (CH2), 52.7 
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(OCH3), 119.7 (q, JC,F = 322.1 Hz, CF3), 119.8 (C), 125.3, 126.3, 126.7, 127.1, 127.6 (CH), 
128.5 (C), 129.5 (CH), 132.8, 133.9 (C), 136.0 (CH), 139.9, 143.5, 143.6 (C), 163.4 (C=O). IR 
(KBr, cm-1): v = 3023, 2960, 2924, 2851 (w), 1716 (s), 1632, 1602, 1516, 1500 (w), 1423 (s), 
1393, 1317, 1265, 1248 (w), 1204, 1136 (s), 1114, 1047, 963, 940 (w), 925, 896, 868, 840, 812, 
796 (m), 719, 677, 632, 608, 591, 574 (w). GC-MS (EI, 70 eV): m/z (%) = 438 ([M]+, 100), 407 
(4), 305 (44), 275 (14), 247 (35), 219 (13), 202 (19). HRMS (EI,70eV): m/z calcd for 
C21H17O5F3S ([M]
+: 438.07433; found: 438.07418. 
 
Methyl 7-(4-methoxyphenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate(5e) 
Starting with 3 (70 mg, 0.145 mmol), 4e (26 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol), and THF (4 mL), 5e was isolated as a white solid 
(53 mg, 83%); mp 142-144 °C. 1H NMR (300 MHz, 
CDCl3): δ = 3.81 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 6.97 (d, J = 8.7 Hz, 2H, ArH), 7.57 (d, J 
= 8.7 Hz, 2H, ArH), 7.67 (s, 1H, ArH), 7.86 (br. s, 2H, ArH), 8.04 (s, 1H, ArH), 8.61 (s, 1H, 
ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.09. 13C NMR (75.5 MHz, CDCl3): δ = 52.7, 55.4 
(OCH3), 114.6 (CH), 117.6 (q, JC,F = 320.8 Hz, CF3), 120.8, 122.3 (C), 125.8, 128.1, 128.5, 
129.4 (CH), 132.1, 133.6 (C), 134.1, 134.9 (CH), 140.6, 144.5, 159.8 (C), 164.4 (C=O). IR 
(KBr, cm-1): v = 3046, 3028 (w), 2958, 2919, 2849 (m), 2663, 1728 (w), 1722 (s), 1681, 1650, 
1644 (m), 1603 (s), 1578, 1557, 1502 (m), 1460 (w), 1425, 1401, 1321 (s), 1282, 1268 (m), 
1246, 1216, 1200 (s), 1115 (m). GC-MS (EI,70 eV ): m/z (%) = 440 ([M]+, 50), 409 (4), 307 
(100), 277 (13), 249 (23), 221 (15), 176 (14). HRMS (ESI-TOF): m/z calcd for C20H16O6F3S 
[M+H]+: 441.06142; found: 441.06173. 
 
Methyl 7-(p-tolyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5f) 
Starting with 3 (70 mg, 0.145 mmol), 4f (24 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol) and THF (4 mL), 5f was isolated as a white solid (48 
mg, 78%); mp: 133-135 °C. 1H NMR (300 MHz, CDCl3): δ 
= 2.36 (s, 3H, CH3), 3.95 (s, 3H, OCH3), 7.24 (d, J = 7.9 Hz, 2H, ArH), 7.52 (d, J = 8.0 Hz, 2H,  
ArH), 7.67 (s, 1H, ArH), 7.86 (br. s, 2H, ArH), 8.06 (s, 1H, ArH), 8.62 (s, 1H, ArH). 19F NMR 
(282.4 MHz, CDCl3): δ = -73.08. 13C NMR (75.5 MHz, CDCl3): δ = 20.1 (CH3), 51.7 (OCH3), 
118.8 (q, JC,F = 320.7 Hz, CF3), 119.8 (CH), 121.3 (C), 125.3, 126.2, 127.1, 128.5, 128.8 (CH), 
130.7, 132.8 (C), 133.9 (CH), 135.8, 137.2, 139.9, 143.6 (C), 163.4 (C=O). IR (KBr, cm-1): v = 
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3033, 3024, 3001 (w), 2985, 2978 (s), 2932, 2896 (m), 2862 (w), 2820 (s), 2764, 2719, 2680, 
2655 (w), 2600, 2558 (s), 2552, 2520, 2487, 2430, 2390 (w), 2327, 1984, 1920 (s), 1690, 1620, 
1570 (w), 1480, 1470, 1390, 1320 (s), 1290, 1245 (m). GC-MS (EI, 70 eV): m/z (%) = 424 
([M]+, 50), 392 (18), 291 (100), 261 (15), 233 (39), 205 (21). HRMS (EI, 70 eV): m/z calcd for 
C20H15O5F3S [M]
+: 424.05868; found: 424.05848. 
 
Methyl 7-(4-ethoxyphenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5g)  
 Starting with 3 (70 mg, 0.145 mmol), 4g (29 mg, 0.174 
mmol), Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 
mmol), and THF (4 mL), 5g  was isolated as a white solid 
(54 mg, 82%); mp 105-108 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.38 (t, J = 7.2 Hz, 3H, CH3), 2.85 (s, 3H, 
OCH3), 3.96 (q, J = 7.2 Hz, 2H, OCH2), 6.88 (d, J = 8.9 Hz, 2H, ArH), 7.23 (d, J = 8.7 Hz, 2H, 
ArH), 7.40 (dd, J = 8.9, 2.5 Hz, 1H, ArH), 7.76 (d, J = 2.3 Hz, 1H, ArH), 7.79 (s, 1H, ArH), 
7.86 (s, 1H, ArH), 8.28 (s, 1H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 20.1 (CH3), 55.4 
(OCH3), 62.5 (OCH2), 113.2 (CH), 118.2 (q, JC,F = 321.3 Hz, CF3), 118.7, 120.1 (C), 120.8, 
128.3 (CH), 128.5 (C), 129.4, 129.6 (CH), 129.9 (C), 130.2, 135.6 (CH), 141.5, 143.7, 158.1 
(C), 167.8 (C=O). IR (KBr, cm-1): v = 3022, 3012, 2987 (w), 2925, 2912 (m), 1756, 1734 (s), 
1722, 1686 (w), 1623 (m), 1605, 1592 (s), 1578, 1557, 1532 (m), 1517 (w), 1463, 1445, 1422, 
1406 (m),  1361, 1333, 1328, 1312 (w), 1282 (m), 1278, 1245, 1232 (w), 1216 (s),  1175, 1132, 
1128, 1116 (m). GC-MS (EI,70eV ): m/z (%) = 454 ([M]+, 46), 322 (23), 321 (100),  293 (15), 
265 (15), 234 (17), 205 (12). HRMS (ESI-TOF): m/z calcd for C21H18F3O6S [M+H]
+: 
455.07707; found: 455.07661. 
 
Methyl 7-(3-methoxyphenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5h) 
Starting with 3 (70 mg, 0.145 mmol), 4h (26 mg, 0.174 mmol),  
K3PO4 (46 mg, 0.22 mmol), Pd(PPh3)4 (5 mg, 3 mol-%), and 
THF (4 mL), 5h was isolated as a white solid (54 mg, 85%); 
mp: 82-83 °C. 1H NMR (300 MHz, CDCl3): δ = 3.83 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 6.89- 6.93 (m, 1H, ArH), 7.14-7.22 
(m, 3H, ArH), 7.36 (t, J = 7.9 Hz, 1H, ArH), 7.69 (br. s, 1H, ArH), 7.87-7.88 (m, 2H, ArH), 
8.09 (br. s, 1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.09. 13C NMR (75.5 MHz, CDCl3): 
δ = 52.7, 55.4 (OCH3), 113.3, 113.4 (CH), 117.9 (q, JC,F = 319.3 Hz, CF3), 119.8, 120.8 (CH), 
122.4 (C), 126.7, 128.2, 129.6, 130.1 (CH), 131.7, 134.1 (C), 135.0 (CH), 140.9, 141.2, 144.7, 
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160.2 (C), 164.4 (C=O). IR (KBr, cm-1): v = 3002, 2954, 2927, 2847 (w), 1726 (s), 1632, 1599, 
1509, 1488, 1459 (w), 1422 (s), 1402, 1370, 1314, 1286, 1263, 1249 (w), 1202, 1136 (s), 1052, 
1031 (m), 969, 939 (w), 897, 853, 810, 792, 776, 722 (m), 696, 667, 643 (w), 609, 600 (m). 
GC-MS (EI, 70 eV): m/z (%) = 440 ([M]+, 59), 308 (20), 307 (100), 277 (15), 249 (50), 221 
(18). HRMS (EI, 70 eV): m/z calcd for C20H15O6F3S [M]
+: 440.05359; found: 440.05333. 
 
Methyl 7-(3-fluorophenyl)-3-(trifluoromethylsulfonyloxy)-2-naphthoate (5i) 
Starting with 3 (70 mg, 0.145 mmol), 4i (24 mg, 0.174 mmol), 
Pd(PPh3)4 (5 mg, 3 mol-%), K3PO4 (46 mg, 0.22 mmol), and 
THF (4 mL), 5i was isolated as a white solid (51 mg, 82%);  mp 
54-56 °C. 1H NMR (300 MHz, CDCl3): δ = 3.96 (s, 3H, OCH3), 
7.25-7.41 (m, 3H, ArH), 7.70 (s, 1H, ArH), 7.79-7.92 (m, 3H, 
ArH), 8.07 (s, 1H, ArH), 8.64 (s, 1H, ArH). 19F NMR (282 MHz, DMSO-d6): δ = -112.3, -73.1. 
13C NMR (75.5 MHz, CDCl3): δ = 52.8 (OCH3), 114.2 (d, JC,F = 21.7 Hz, CH), 114.9 (d, JC,F = 
22.4 Hz, CH), 115.2 (C), 119.4 (q, JC,F = 321.8 Hz, CF3), 120.9 (CH), 122.6 (C), 123.1, 126.9, 
128.5, 129.3, 129.7 (CH), 130.7 (d, JC,F = 8.3 Hz, CH), 131.7 (d, JC,F = 3.2 Hz, CH), 134.7 (d, 
JC,F = 8.9 Hz, C), 135.1 (CH), 142.0, 145.0 (C), 164.9 (d, JC,F = 245.2 Hz, CF), 168.8 (C=O). 
IR (KBr, cm-1): v = 3079, 3038, 2956, 2918, 2849 (w), 1720 (s), 1633, 1602, 1586, 1511, 1488 
(w), 1420 (s), 1371, 1321, 1284, 1248 (w), 1201, 1135 (s). GC-MS (EI,70eV ): m/z (%) = 428 
([M]+, 38), 295 (62), 269 (20), 267 (75), 265 (14), 264 (13), 237 (100), 236 (29), 209 (39), 207 
(64). HR-MS (ESI-TOF/MS, 70 eV): m/z calcd. for C19H12O5F4S [M+H]
+: 429.04234; found: 
429.04275.  
 
Methyl 7-(p-methoxyphenyl)-3-(p-tolyl)-2-naphthoate (6) 
 The reaction was carried out in a pressure tube. To the 
THF suspension (4 mL) of 3 (70 mg, 0.145 mmol), 
arylboronic acid Ar1B(OH)2 4e (22 mg, 0.145 mmol),  
and Pd(PPh3)4 (5 mg, 3 mol%) was added K3PO4 (46 mg, 
0.22 mmol), and the resulting solution was degassed by 
bubbling argon through the solution for 10 min. The 
mixture was stirred at 20°C under an argon atmosphere for 9 h. Arylboronic acid Ar2B(OH)2 4f 
(20 mg, 0.145 mmol), Pd(PPh3)4 (3 mol-%), K3PO4 (46 mg, 0.22 mmol) were added. The 
reaction mixtures were heated under an argon atmosphere at 105 °C for 8 h. They were diluted 
with H2O and extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were dried 
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(Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography (silica gel, heptane/EtAOc). 6 was isolated as a white solid (25 mg, 45 %); mp 
82-83°C. 1H NMR (300 MHz, CDCl3): δ = 2,36 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 3.96 (s, 3H, 
OCH3), 6.91 (d, J = 8.8 Hz, 2H, ArH), 7.23-7.31 (m, 4H, ArH), 7.56 (d, J = 8.8 Hz, 2H, ArH), 
7.74 (s, 1H, ArH), 7.75-7.77 (m, 2H, ArH), 7.82 (s, 1H, ArH), 8.06 (s, 1H, ArH). 13C NMR 
(75.5 MHz, CDCl3): δ = 20.1 (CH3), 52.7, 55.4 (OCH3), 113.1, 119.8 (CH), 121.3 (C), 125.3, 
126.2, 126.7, 127.1, 128.5, 128.8 (CH), 130.8, 132,9 (C), 133.9 (CH), 134.2, 134.6, 135.8, 
137.2, 139.9, 143.6 (C), 164.3 (C=O). IR (KBr, cm-1): v = 3002, 2954, 2927, 2847 (w), 1726 
(s), 1632, 1599, 1509, 1488, 1459 (w), 1422 (s), 1402, 1370, 1314, 1286, 1263, 1249 (w), 1202, 
1136 (s), 1052, 1031 (m), 969, 939 (w), 897, 853, 810, 792, 776, 722 (m), 696, 667, 643 (w), 
609, 600 (m). GC-MS (EI, 70eV): m/z (%) = 382 ([M]+, 87), 367 (09), 311 (100), 281 (23), 207 
(50), 198 (18). HR-MS (ESI-TOF): m/z calcd. for C26H22O3 [M+H]
+: 383.15678; found: 
383.15623. 
 
Methyl 4-bromo-3-hydroxy-2-naphthoate (8) 
To a solution of 4-bromo-3-hydroxy-2-naphthoic acid 7 (1.0 g, 3.7 
mmol) in DMF (15 mL), dimethyl sulfate (1.04 g, 8.3 mmol) and N,N-  
diisopropylethylamine (0.5 g, 4.1 mmol) were added. The reaction 
mixture was heated for 1 h at 85 °C. After cooling to room temperature, 
the mixture was poured into ice water. A white precipitate formed which was filtered off and 
the filtrate was concentrated in vacuo. The product 8 was isolated by column chromatography 
(flash silica gel, heptane/EtOAc) as a yellow solid (0.9 g, 87 %); mp 88 - 95 °C. 1H NMR (250 
MHz, CDCl3): δ = 3.96 (s, 3H, OCH3), 7.27-7.33 (m, 1H, ArH), 7.52-7.58 (m, 1H, ArH), 7.70 
(d, J = 8.2 Hz, 1H, ArH), 8.07 (d, J = 8.5 Hz, 1H, ArH), 8.36 (s, 1H, ArH), 11.16 (s, 1H, OH). 
13C NMR (62.90 MHz, CDCl3):  = 52.0 (OCH3), 106.0, 113.6 (C), 123.6, 124.8 (CH), 126.4 
(C), 128.7, 129.5, 130.8 (CH), 135.1, 152.1 (C), 169.0 (CO). IR (KBr, cm-1): v = 3329 (m), 
3039, 3004, 2955 (w), 1684 (m), 1652, 1634, 1609, 1574, 1557 (w), 1532 (m), 1504, 1479, 
1464 (w), 1399, 1360, 1280, 1213, 1100 (s), 967, 901 (w), 830, 760, 680 (s). GC-MS (EI, 70 
eV): m/z (%) = 282 ([M, 81Br]+, 37),  280 ([M, 79Br ]+, 40),  250 (94), 248 (92), 251 (43), 194 
(100), 192 (18). HRMS (EI, 70 eV) calcd. for C12H9BrO3 [M, 
81Br]+:281.98970; found: 
281.98921; calcd for C12H9BrO3 [M, 
79Br]+: 279.99351;  found: 279.99354. 
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Methyl 4-bromo-3-(trifluoromethylsulfonyloxy)-2-naphthoate (9) 
 To a CH2Cl2 solution (50 mL) of 8 (1.0 g, 3.6 mmol) was added pyridine 
(1.1 mL, 14.2 mmol) and the solution was stirred at 20 °C for 10 min 
under argon atmosphere. Then Tf2O (1.5 mL, 8.6 mmol) was added at 
20 °C and the reaction mixture was heated at 50 °C for 20 min. The 
reaction mixture was filtered and the filtrate was concentrated in vacuo. The product 9 was 
isolated by column chromatography (flash silica gel, heptane/EtOAc) as a colourless solid (1.33 
g, 90 %); mp 90 - 92 oC. 1H NMR (300 MHz, CDCl3): δ = 3.96 (s, 3H, OCH3), 7.59-7.64 (m, 
1H, ArH), 7.70-7.75 (m, 1H, ArH), 7.91 (d, J = 8.1 Hz, 1H, ArH), 8.29 (d, J = 8.5 Hz, 1H,  
ArH), 8.47 (s, 1H, ArH). 13C NMR (75.5 MHz, CDCl3)  = 53.0 (OCH3), 117.7 (C), 118.5 (q, 
JC,F = 317.4 Hz, CF3), 123.8, 128.1 (CH), 128.6 (C), 129.5, 130.8, 131.6 (CH), 133.4, 134.2, 
142.4 (C), 164.6 (CO). IR (KBr, cm-1):  v = 3071, 2962 (w), 1714 (s), 1676, 1630 (w), 1598 
(m), 1503, 1462, 1441 (w), 1427 (w), 1345, 1233 (s), 1143, 1102, 985, (m), 865, 750, 701, 633 
(w). GC-MS (EI, 70 eV): m/z (%) =  414 ([M, 81Br]+, 25),  412 ([M, 79Br ]+, 26), 281 (40), 279 
(43), 251 (100), 248 (24), 223 (36), 221 (32). HRMS (EI, 70 eV) calcd for C13H8BrF3O5S [M, 
81Br]+:413.99740; found: 413.99696; calcd for C13H8BrF3O5S [M, 79Br]+: 411.98531;  found: 
411.98491.  
 
General procedure for the synthesis of 10a-g 
A solution of 9 (50 mg, 0.122 mmol), K2CO3 (2M, 2 mL), Pd(PPh3)4 (6 mmol-%) and 
arylboronic acid 4 (2.4 equiv.) in 1,4-dioxane (3 mL) was stirred at 120 °C for 6 h under argon 
atmosphere. To the reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic 
and the aqueous layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). 
The combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
Methyl 3,4-bis(3-methylphenyl)-2-naphthoate (10a) 
 Starting with 9 (50 mg, 0.122 mmol), 4b (39 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 
mL), 10a was isolated as a white solid (32 mg, 72 %); mp 95-97 °C. 
1H NMR (300 MHz. CDCl3): δ = 2.12 (s, 3H, CH3), 2.18 (s, 3H, CH3), 
3.53 (s, 3H, OCH3), 6.74-6.84 (m, 5H,  ArH), 6.92-6.98 (m, 2H,  
ArH), 7.02-7.08 (m, 1H, ArH), 7.35-7.50 (m, 3H, ArH), 7.89 (d, J = 
8.51 Hz, 1H, ArH), 8.28 (s, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 21.2 (CH3), 21.3 
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(CH3), 53.4 (OCH3), 126.3, 126.84, 126.88, 126.9, 127.1, 127.3, 127.6, 127.8, 128.0, 128.6 
(CH), 129.2 (C), 129.4 (CH), 130.3 (C), 130.6 (CH), 131.6 (C), 131.7 (CH), 133.8, 136.3, 136.9, 
137.0, 138.2, 139.9 (C), 169.2 (C=O). IR (KBr, cm-1): v = 3028, 2946, 2918, 2857, 2732 (w), 
1727 (s), 1621, 1604, 1584, 1484 (w), 1436 (m), 1372, 1332 (w), 1301 (s), 1267 (m), 1226, 
1202, 1190, 1163 (s), 1126 (m), 1101, 1087 (s), 1033, 1022 (m), 999, 970 (w). GC-MS (EI, 70 
eV): m/z (%) = 366 ([M]+, 100), 335 (32), 319 (10), 292 (13), 291 (12), 289 (14), 276 (14). 
HRMS (EI, 70 eV) calcd. for   C26H22O2 [M]+: 366.16143; found: 366.16095. 
 
Methyl 3,4-bis(4-chlorophenyl)-2-naphthoate (10b) 
Starting with 9 (50 mg, 0.122 mmol), 4c (45 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane 
(3 mL), 10b was isolated as a white solid (34 mg, 69 %); mp 81-
84 °C. 1H NMR (300 MHz, CDCl3): δ = 3.57 (s, 3H, OCH3), 6.85-
6.96 (m, 4H, ArH), 7.05-7.09 (m, 2H, ArH), 7.17-7.19 (m, 2H, 
ArH), 7.40-7.53 (m, 3H, ArH), 7.92 (d, J = 7.5  Hz, 1H,  ArH), 8.37 
(s, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 52.15 (OCH3), 
126.6, 126.8, 127.5, 128.2, 128.5, 128.9 (CH), 129.6 (C), 130.6, 131.1 (CH), 131.8 (C), 132.2 
(CH), 132.4, 133.0, 133.6, 135.9, 136.5, 138.3, 138.7 (C), 168.4 (C=O). IR (KBr, cm-1): v = 
3057, 2961, 2925, 2855, 1716 (w), 1608, 1589 (m), 1536, 1482 (w), 1235, 1209 (m), 1137, 
1117, 1095, 1070 (s). GC-MS (EI, 70 eV): m/z (%) = 408 ([M, 37Cl]+, 68), 406 ([M, 35Cl]+, 100) 
410 (12), 409 (18), 377 (24), 375 (37), 340 (17), 312 (24), 277 (18), 274 (18). HRMS (EI, 70 
eV) calcd. for C24H16O2Cl2 [M, 35Cl]+: 406.05219; found:406.05154; calcd. for C24H16O2Cl2 
[M, 73Cl]+: 408.04924; found: 408.04910.  
 
Methyl 3,4-bis(4-ethylphenyl)-2-naphthoate (10c) 
Starting with 9 (50 mg, 0.122 mmol), 4d (43 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole  %), K2CO3 (2M, 2 mL) and 1,4-dioxane 
(3 mL), 10c was isolated as a white solid (39 mg, 81 %);  mp 92-
95 °C. 1H NMR (250 MHz, CDCl3): δ = 1.12 (m, 6H, 2CH3), 2.52 
(dq, J = 18.4, 7.6 Hz, 4H, 2CH2), 3,51 (s, 3H, OCH3), 6.84-6.92 
(m, 6H, ArH), 6.99 (d, J = 8.12 Hz, 2H, ArH), 7.35-7.52 (m, 3H, 
ArH), 7.88 (d, J = 7.8 Hz, 1H, ArH), 8.26 (s, 1H, ArH). 13C NMR 
(62.9 MHz, CDCl3): δ =14.4 (CH3), 14.5 (CH3), 27.4 (CH2), 27.5 (CH2), 51.9 (OCH3), 125.3, 
125.5 (C), 126.3, 126.6, 127.0, 127.1, 127.8, 128.7, 129.3, 129.8, 130.9 (CH), 133.0, 134.6, 
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136.0, 136.3, 138.9, 140.8, 141.4 (C), 168.3 (C=O). IR (KBr, cm-1): v = 3059, 3022 (w), 2965, 
2945 (m), 2930, 2871 (w), 1720 (s), 1618, 1591 (w), 1513 (m), 1490 (w), 1453, 1443, 1424, 
1405 (m), 1370, 1334 (w), 1300, 1261, 1232, 1208 (s), 1179, 1149, 1127 (w), 1115 (m). GC-
MS (EI, 70 eV): m/z (%) = 394 ([M]+, 100),  347 (10), 305 (11), 289 (17), 276 (10). HRMS (EI, 
70 eV) calcd. for C28H26O2 [M]+: 394.19273; found: 394.19229. 
 
Methyl 3,4-bis(4-methoxyphenyl)-2-naphthoate (10d)  
 Starting with 9 (50 mg, 0.122 mmol), 4e (44 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane 
(3 mL), 10d was isolated as a white solid (42 mg, 86 %); mp 113 
- 115 °C. 1H NMR (250 MHz, CDCl3): δ = 3.56 (s, 3H, OCH3), 
3.68 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 6.63 (d, J = 8.8 Hz, 2H, 
ArH), 6.73 (d, J = 8.8 Hz, 2H, ArH), 6.87 (d, J = 8.7 Hz, 2H, ArH), 
6.92 (d, J = 8.8 Hz, 2H, ArH), 7.35-7.51 (m, 3H, ArH), 7.89 (d, J 
=8.4 Hz, 1H, ArH), 8.25 (br. s, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 52.1, 55.0, 55.1 
(OCH3), 112.7, 113.2, 126.3, 126.9, 127.8, 128.7, 129.3 (CH), 130.7, 130.8 (C), 130.9 (CH), 
131.6 (C), 132.1 (CH), 132.5, 134.2, 136.8, 139.7, 157.8, 158.2 (C), 169.5 (C=O). IR (KBr, cm-
1): v = 3243, 3152, 2862, 2800, 2739 (w), 1700 (m), 1655 (s), 1614, 1428, 1405 (m), 1377, 1315 
(w), 1298 (m), 1233 (w), 1201, 1184, 1144, 1115 (s). GC-MS (EI, 70 eV): m/z (%) = 398 ([M]+, 
100), 367 (13), 256 (16). HRMS (EI, 70 eV) calcd. for   C26H22O4 [M]+: 398.15126; found: 
398.15102. 
 
Methyl 3,4-bis(4-methylphenyl)-2-naphthoate (10e) 
 Starting with 9 (50 mg, 0.122 mmol), 4f (39 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 
mL), 10e was isolated as a white solid (35 mg, 78 %); mp 97 - 100 °C. 
1H NMR (250 MHz, CDCl3): δ = 2.19 (s, 3H, CH3), 2.25 (s, 3H, CH3), 
3.54 (s, 3H, OCH3), 6.82-6.86 (m, 4H, ArH), 6.89 (d, J = 8.04 Hz, 
2H, ArH), 6.98 (d, J = 7.8 Hz, 2H, ArH), 7.33-7.47 (m, 2H, ArH), 
7.86-7.90 (m, 2H, ArH), 8.26 (br. s, 1H, ArH). 13C NMR (62.9 MHz, 
CDCl3): δ = 21.2 (CH3), 29.7 (CH3), 55.2 (OCH3), 126.3, 127.0, 127.8, 127.9, 128.3, 128.6, 
129.4, 129.7 (CH), 130.6 (C), 130.9 (CH), 131.6, 134.0, 135.4, 135.5, 136.1, 136.9, 137.1, 
139.9 (C), 169.3 (C=O). IR (KBr, cm-1): v = 3043, 3022, 2952, 2918, 2849, 1900 (w), 1716 (s), 
1514, 1488, 1435 (m), 1417, 1408 (w), 1379 (m), 1333 (w), 1301, 1262, 1232, 1207, 1180 (s), 
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1153, 1128 (m). GC-MS (EI, 70 eV): m/z (%) = 366 ([M]+, 100), 335 (29), 319 (12), 306 (12), 
292 (16), 291 (13), 289 (18). HRMS (EI, 70 eV) calcd. for C26H22O2 [M]+: 366.16134; found: 
366.16134. 
 
Methyl 3,4-bis(4-ethoxyphenyl)-2-naphthoate (10f)  
 Starting with 9 (50 mg, 0.122 mmol), 4g (48 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-
dioxane (3 mL), 10f was isolated as a white solid (48 mg, 93%);  
mp 102 - 105 °C. 1H NMR (250 MHz, CDCl3): δ = 1.28-1.35 
(m, 6H, 2CH3), 3.54 (s, 3H, OCH3), 3.84-3.97 (m, 4H, 2OCH2), 
6.60 (d, J = 8.6 Hz, 2H, ArH), 6.71 (d, J = 8.6 Hz, 2H,  ArH), 
6.85 (d, J = 8.6 Hz, 2H, ArH), 6.9 (d, J = 8.8 Hz, 2H,  ArH), 
7.34-7.51 (m, 3H, ArH), 7.87 (d, J = 7.4 Hz, 1H, ArH), 8.23 (br. 
s,1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 14.9, 29.7 (2CH3), 52.1 (OCH3), 63.2, 63.3 
(2OCH2), 113.3, 113.7, 126.3, 127.0, 127.8, 128.7, 129.2 (CH), 130.6, 130.8 (C), 130.9 (CH), 
131.7 (C), 132.1 (CH), 132.4, 134.2, 136.8, 139.8, 157.2, 157.6 (C), 169.5 (C=O). IR (KBr, cm-
1): v = 3044, 2979, 2950, 2921, 2894, 2873, 2849 (w), 1721, 1715, 1608 (s), 1573 (w), 1512 (s), 
1489, 1473, 1441, 1390, 1376 (m), 1331 (w), 1300 (s), 1284, 1258 (m), 1240, 1205, 1174 (s), 
1129 (w), 1112 (s), 1097 (m), 1045 (s). GC-MS (EI, 70 eV): m/z (%) = 426 ([M]+, 100), 281 
(10), 252 (10). HRMS (EI, 70 eV) calcd. for C28H26O4 [M]+: 426.18256; found: 426.18189. 
 
Methyl 3,4-bis(4-trifluoromethylphenyl)-2-naphthoate (10g) 
 Starting with 9 (50 mg, 0.122 mmol), 4j (55 mg, 0.29 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane 
(3 mL), 10g was isolated as a white solid (42 mg, 73 %); mp 94 - 
97 °C. 1H NMR (300 MHz. CDCl3): δ =  3.56 (s, 3H, OCH3), 7.08 
(d, J = 7.9 Hz, 2H, ArH), 7.13 (d, J = 7.9 Hz, 2H, ArH), 7.34 (d, J 
= 8.5 Hz, 3H, ArH), 7.43-7.48 (m, 3H, ArH), 7.53 (dd, J = 8, 1.4 
Hz, 1H, ArH), 7.95 (d, J = 7.9 Hz, 1H, ArH), 8.46 (s, 1H, ArH). 
19F NMR (282.4, MHz): δ = -62.52, -62.60. 13C NMR (62.9 MHz, CDCl3): δ = 51.2 (OCH3), 
123.2 (q, JC,F = 3.9 Hz, CH), 123.7 (CH), 123.8 (q, JC,F = 3.3 Hz, CH), 124.0 (q, JC,F = 271 Hz, 
CF3), 124.1 (q, JC,F = 271 Hz, CF3), 125.4, 126.1 (C), 127.8, 128.0, 128.1, 129.1, 130.2 (CH), 
130.9 (q, JC,F = 31 Hz, C), 131.1 (q, JC,F = 35 Hz, C), 132.4, 134.8, 137.5, 140.8, 142.5 (C), 
167.2 (C=O). IR (KBr, cm-1): v = 3313, 3252 (w), 2962, 2870 (m), 2659, 1900 (w), 1785, 1754, 
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1608 (s), 1585, 1490, 1415 (w), 1328 (m), 1283, 1251 (s), 1154 (m). GC-MS (EI, 70 eV): m/z 
(%) = 474 ([M]+, 100), 444 (14), 443 (57), 423 (13), 346 (23), 345 (10), 344 (13), 276 (22). 
HRMS (EI, 70 eV) calcd. for C26H16O2F6 [M]+: 474.10490; found: 474.10420. 
 
General procedure for the synthesis of 11a-e 
 A 1,4-dioxan solution of 9 (50 mg, 0.122 mmol), K2CO3 (2M, 2 mL), Pd(PPh3)4 (3 mol-%) and 
of arylboronic acid 4 (1.0 equiv.) was stirred at 60 °C for 9 h under argon atmosphere. To the 
reaction mixture were added H2O (20 mL) and CH2Cl2 (25 mL). The organic and the aqueous 
layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, heptane / EtOAc = 100:5). 
 
Methyl 4-bromo-3-(3-methylphenyl)-2-naphthoate (11a) 
 Starting with 9 (50 mg, 0.122 mmol), 4b (17 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane (3 
mL), 11a was isolated as a white solid (36 mg, 83 %); mp 105 - 108 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.34 (s, 3H, CH3), 3.53 (s, 3H, OCH3), 
6.77 (s, 1H, ArH), 7.01 (d, J = 7.1 Hz, 2H, ArH), 7.14-7.16 (m, 1H, ArH), 
7.24-7.29 (m, 1H, ArH), 7.51-7.56 (m, 1H, ArH), 7.64 (ddd, J = 8.5, 7, 1.3 Hz, 1H, ArH), 7.87 
(d, J = 7.9 Hz, 1H, ArH), 8.33 (d, J = 8.7 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 20.5 
(CH3), 51.17 (OCH3), 125.3, 126.3, 126.6, 127.1, 127.2 (CH), 127.6 (C), 128.1, 128.6, 128.8, 
128.9 (CH), 129.6, 131.5, 132.6, 136.2, 138.4, 140.1 (C), 166.7 (C=O). IR (KBr, cm-1): v = 
3050, 3023 (w), 2984, 2921 (m), 2845 (w), 1728 (s), 1621, 1545, 1512 (w), 1484, 1439 (m), 
1375, 1322, 1303 (w), 1256, 1232, 1190 (s). GC-MS (EI, 70 eV): m/z (%) = 356 ([M, 81Br]+, 
83), 354 ([M, 79Br]+, 83),  357 (17), 325 (19), 323 (19), 260 (10),  244 (100), 243 (18), 216 (21). 
HRMS (EI, 70 eV) calcd. for C19H15BrO2 [M, 79Br]+: 354.02499; found: 354.02481; calcd. for 
C19H15BrO2 [M, 81Br]+: 356.02295; found: 354.02303. 
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Methyl 4-bromo-3-(4-chlorophenyl)-2-naphthoate (11b) 
 Starting with 9 (50 mg, 0.122 mmol),  4c (19 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane 
(3 mL), 11b was isolated as a white solid (34 mg, 76 %); mp 88-
91°C. 1H NMR (250 MHz, CDCl3): δ = 3.58 (s, 3H, OCH3), 7.12-
7.16 (m, 2H, ArH), 7.35 (d, J = 8.5 Hz, 2H, ArH), 7.53-7.70 (m, 2H, 
ArH), 7.88 (dd, J = 8.1, 1.2  Hz, 1H, ArH), 8.33 (d, J = 8.9 Hz, 2H, ArH). 13C NMR (62.9 MHz, 
CDCl3): δ = 52.3 (OCH3), 124.6, 126.4 (C), 127.6, 128.0, 128.1, 129.2, 129.8, 130.4, 130.5 
(CH), 131.5, 132.4, 132.5, 137.2, 138.7 (C), 166.2 (C=O). IR (KBr, cm-1): v = 3100, 3083, 3051, 
2997, 2947, 2918, 2849 (w), 1730, 1720 (s), 1621, 1596, 1555 (w), 1494, 1439, 1395, 1346, 
1314 (m), 1263, 1227, 1208, 1140, 1099, 1083 (s), 1029 (w). GC-MS (EI, 70 eV): m/z (%) = 
376 ([M, 81Br, 35Cl]+, 100), 374 ([M, 79Br, 35Cl]+, 75), 345 (28), 343 (22), 280 (14), 266 (26), 
265 (19), 264 (77), 238 (10), 199 (13). HRMS (EI, 70 eV) calcd. for C18H12BrO2Cl 
[M,79Br,35Cl]+: 373.97032; found: 373.97039; calcd. for  C18H12BrO2Cl [M,81Br,35Cl]+: 
375.96832; found: 375.96804. 
 
Methyl 4-bromo-3-(4-ethylphenyl)-2-naphthoate (11c) 
 Starting with 9 (50 mg, 0.122 mmol), 4d (18 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane 
(3 mL), 11c was isolated as a white solid (39 mg, 88 %); mp 101-
104 °C.1H NMR (300 MHz, CDCl3): δ =1.23 (m, 3H, CH3), 2.67 
(m, 2H, CH2), 3.52 (s, 3H, OCH3),  7.12 (d, J = 8.31 Hz, 2H,  ArH), 
7.18-7.22 (m, 3H,  ArH), 7.50-7.55 (m, 1H,  ArH), 7.63 (ddd, J = 8.5, 7, 1.3 Hz, 1H, ArH), 7.86 
(d, J = 7.1 Hz, 1H, ArH), 8.32 (d, J = 8.50 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 
15.3 (CH3), 28.7 (CH2), 52.2 (OCH3), 125.5 (C), 127.2, 127.3, 128.1, 129.0, 129.1, 129.5, 129.8 
(CH), 130.8, 132.4, 133.6, 138.4, 139.3, 143.4 (C), 167.8 (C=O). IR (KBr, cm-1): v = 3050, 
3020 (w), 2961, 2927, 2871, 2855 (m), 1729 (s), 1621, 1553 (w), 1515, 1484 (m), 1437 (s), 
1409, 1373, 1346 (m), 1282, 1262, 1233, 1202 (s), 1145 (w), 1138, 1116 (s). GC-MS (EI, 70 
eV): m/z (%) = 370 ([M, 81Br]+, 56), 368 ([M, 79Br]+, 100), 314 (15), 251 (17), 149 (10). HRMS 
(EI, 70 eV) calcd. for C20H17BrO2 [M, 79Br]+: 368.04221; found: 368.04102; calcd. for 
C20H17BrO2 [M, 81Br]+: 370.03921; found: 370.03100. 
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Methyl 4-bromo-3-(4-methoxyphenyl)-2-naphthoate (11d) 
 Starting with 9 (50 mg, 0.122 mmol), 4e (19 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane 
(3 mL), 11d was isolated as a white solid (41 mg, 92 %); mp 107 
- 110 °C. 1H NMR (300 MHz, CDCl3): δ = 3.56 (s, 3H, OCH3), 
3.81 (s, 3H, OCH3), 6.91 (d, J = 8.69 Hz, 1H, ArH), 7.11-7.19 (m, 
3H,  ArH), 7.50-7.56 (m, 1H, ArH), 7.64 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H, ArH), 7.86 (d, J = 7.93 
Hz, 1H, ArH), 8.25 (s, 1H, ArH), 8.32 (d, J = 8.69 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): 
δ = 52.3, 55.2 (OCH3), 113.2 (CH), 125.9 (C), 127.3, 128.1, 129.0, 129.5, 129.8, 130.5 (CH), 
132.4, 133.5, 133.6, 137.8, 138.9, 142.2 (C), 167.9 (C=O). IR (KBr, cm-1): v = 3041, 3000, 
2951, 2931, 2849, 2832, 1881 (w), 1729 (s), 1607 (m), 1575, 1552 (w), 1513 (s), 1483 (w), 
1455 (m), 1436 (s), 1346, 1314, 1304, 1285 (m), 1257, 1238, 1229, 1200, 1177, 1135, 1099, 
1029 (s). GC-MS (EI, 70 eV): m/z (%) = 372 ([M, 81Br]+, 100), 370 ([M, 79Br]+, 100),  339 (11), 
261 (16), 260 (68), 245 (22), 217(10). HRMS (EI, 70 eV) calcd. for C19H15BrO3 [M, 79Br]+: 
370.01991; found: 370.01940; calcd. for C19H15BrO3 [M, 81Br]+: 372.01786; found: 372.01693. 
 
Methyl 4-bromo-3-(4-methylphenyl)-2-naphthoate (11e) 
 Starting with 9 (50 mg, 0.122 mmol),  4f  (17 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane (3 
mL), 11e was isolated as a white solid (34 mg, 79 %); mp 104- 107 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H, CH3), 3.55 (s, 3H, 
OCH3), 6.85-6.91 (m, 1H, ArH), 7.10 (d, J = 8.12 Hz, 2H, ArH), 7.17-
7.20 (m, 2H, ArH), 7.51-7.56 (m, 1H, ArH), 7.65 (ddd, J = 8.5, 7, 1.3  Hz, 1H, ArH), 7.87 (d, J 
= 7.93 Hz, 1H, ArH), 8.33 (d, J = 8.69 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 21.5 
(CH3), 52.23 (OCH3), 127.4, 127.9, 128.1 (CH), 128.4 (C), 128.5, 129.1, 129.6, 129.9 (CH), 
130.7, 132.5, 137.1, 138.3, 139.4, 139.9 (C), 167.9 (C=O). IR (KBr, cm-1): v = 3049, 3020, 
2993, 2947 (w), 2920, 2853 (m), 1728 (s), 1621, 1591, 1554 (w), 1515, 1484 (m), 1438 (s), 
1376, 1345 (w), 1322, 1300 (m), 1261, 1228, 1203, 1183 (s), 1150, 1138 (m), 1097 (s). GC-MS 
(EI, 70 eV): m/z (%) = 356 ([M, 81Br]+, 81), 354 ([M, 79Br]+, 81), 357 (17), 325 (16), 260 (11), 
243 (17), 242 (100), 214 (11). HRMS (EI, 70 eV) calcd. for C19H15BrO2 [M, 79Br]+: 354.02499; 
found: 354.02459; calcd. for C19H15BrO2 [M, 81Br]+: 356.02295; found: 356.02276. 
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General procedure for the synthesis of 12a-c 
A dioxan solution of 9 (50 mg, 0.122 mmol), Ar1B(OH)2 (1.0 equiv.), K2CO3 2M (2mL) and 
Pd(PPh3)4 (3 mol-%) was heated at 60 °C for 9 h under argon atmosphere. After cooling to 
20 °C, Ar2B(OH)2 (1.2 equiv), Pd(PPh3)4 (6 mol-%) were added and the reaction mixture was 
heated at 120 °C for further 6 h. The reaction mixture was cooled again to 20 °C, H2O was 
added and the reaction mixture was extracted with CH2Cl2 (3 x 25 mL).The combined organic 
layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc / heptanes). 
 
Methyl 3-(4-ethylphenyl)-4-(4-trifluoromethylphenyl)-2-naphthoate (12a)  
Starting with 9 (50 mg, 0.122 mmol),  4d (18 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane 
(3 ml), and 4j (28 mg, 0.146 mmol), Pd(PPh3)4 (8 mg, 6 mole %), 
K2CO3 (2M, 2 mL) and 1,4-dioxane  (3 mL), 12a was isolated as 
a white solid (41 mg, 79%); mp 98-101 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.08 (t, J = 7.6, 2 Hz, 3H, CH3), 2.49 (q, J = 7.6, 3 
Hz, 2H, CH2), 3.53 (s, 3H, OCH3), 6.81-6.88 (m, 4H, ArH), 7.13-
7.18 (m, 3H, ArH), 7.37-7.49 (m, 4H, ArH), 7.92 (d, J = 7.9 Hz, 1H, ArH), 8.33 (s, 1H, ArH). 
19F NMR (282.4, MHz): δ = -62.48. 13C NMR (62.9 MHz, CDCl3): δ = 14.3 (CH3), 27.4 (CH2), 
51.0 (OCH3), 121.4 (C), 123.5 (q, JC,F = 3.6 Hz, CH), 124.6 (q, JC,F = 245 Hz, CF3), 126.8, 128.3, 
128.9, 129.7, 130.2 (CH), 131.4 (q, JC,F = 31 Hz, CF), 132.3, 135.6, 137.3, 141.4 (C), 167.8 
(C=O). IR (KBr, cm-1): v = 3451 (w), 3036, 2985, 2948, 2921 (w), 2856, 2744, 1962, 1935 (w), 
1846, 1793 (m), 1732 (s), 1692 (w), 1576, 1534, 1478 (m), 1443, 1412 (w), 1376, 1344, 1317 
(m), 1265, 1255 (s), 1232, 1201 (w), 1192 (s). GC-MS (EI, 70 eV): m/z (%) = 434 ([M]+, 100), 
419 (21), 405 (11), 403 (16), 387 (12), 375 (12), 373 (10), 359 (10), 289 (15), 276 (17). HRMS 
(EI, 70 eV) calcd. for   C27H21O2F3 [M]
+: 434.14882; found: 434.14868. 
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Methyl 4-(p-methoxyphenyl)-3-(p-tolyl)-2-naphthoate (12b)  
 Starting with 9 (50 mg, 0.122 mmol), 4f (17mg, 0122 mmol), K2CO3 
(2M, 2 mL) , Pd(PPh3)4 (4 mg, 3 mol-%) and 4e (22 mg, 0.146 mmol), 
Pd(PPh3)4 (8 mg, 6 mole %), K2CO3 (2M, 2 mL) and 1,4-dioxane  (3 
mL), 12b was isolated as a white solid (39 mg, 86 %); mp 87-88 °C 
.1H NMR (300 MHz, CDCl3): δ = 2.21 (s, 3H, CH3), 3.54 (s, 3H, 
OCH3), 3.73 (s, 3H, OCH3), 6.73 (d, J = 8.9 Hz, 2H, ArH), 6.82-6.90 
(m, 4H, ArH), 6.93 (d, J = 8.7 Hz, 2H, ArH), 7.35-7.45 (m, 2H, ArH), 
7.47-7.50 (m, 1H, ArH), 7.88 (br. d, J = 7.7 Hz, 1H, ArH), 8.3 (s, 1H, ArH). 13C NMR (75.5 
MHz, CDCl3): δ =  29.9 (CH3), 51.0, 54.2 (OCH3), 112.1 (C), 113.1, 119.8 (CH), 125.3, 125.8 
(C), 126.3 (CH), 126.9, 127.7 (C), 127.8, 127.9 (CH), 128.4, 128.7 (C), 128.9 (CH), 131.1 (C), 
131.7, 132.1 (CH), 134.2 (C),  135.7 (CH), 169.4 (C=O). IR (KBr, cm-1): v = 3003, 2956, 2928, 
2849 (w), 1727 (s), 1634, 1598, 1507, 1489 (m), 1346, 1277, 1209, 1144 (s), 976, 944, 855, 
820, 744 (m), 699, 640 (s). GC-MS (EI,70eV ) : m/z (%) = 382 ([M]+, 88), 370 (78), 311 (100), 
298 (21), 245 (33), 198 (18). HRMS (EI, 70 eV) calcd for C26H22O3 [M]
+:382.01653; found: 
382.01693. 
 
Methyl 3-(4-chlorophenyl)-4-(4-ethylphenyl)-2-naphthoate (12c) 
 Starting with 9 (50 mg, 0.122 mmol),  4c (19 mg, 0.122 mmol), 
Pd(PPh3)4 (4 mg, 3 mole %), K2CO3  (2M, 2 mL), and 1,4-dioxane 
(3 mL), and 4d (22 mg, 0.146 mmol), Pd(PPh3)4 (8 mg, 6 mole %), 
K2CO3 (2M, 2 mL) and 1,4-dioxane (3 mL), 12c was isolated as a 
white solid (35 mg, 71%); mp 112-115 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.20 (m, 3H, CH3), 2.57 (q, J = 7.3, 3 Hz, 2H, CH2), 
3.57 (s, 3H, OCH3), 6.88-6.91 (m, 4H, ArH), 7.00-7.06 (m, 4H, 
ArH), 7.37-7.50 (m, 3H, ArH), 7.88-7.90 (m, 1H, ArH), 8.33 (s, 1H, ArH). 13C NMR (62.9 
MHz, CDCl3): δ = 14.3 (CH3), 27.4 (CH2), 51.0 (OCH3), 125.6, 126.1, 126.2, 126.3, 127.1, 
127.7 (CH), 128.7 (C), 128.9, 129.7, 130.2 (CH), 130.8, 131.1, 133.1, 134.1, 134.7, 137.8, 
139.2, 141.8 (C), 167.7 (C=O). IR (KBr, cm-1): v = 3422, 3365 (w), 2964, 2902 (m), 2835, 
2831, 2780 (w), 1983, 1934, 1868 (m), 1721 (s), 1650, 1577, 1562, 1492, 1445 (m), 1432 (s), 
1388, 1376, 1322 (w), 1281, 1264, 1218 (s), 1194, 1163, 1114 (m). GC-MS (EI, 70 eV): m/z 
(%) = 402([M, 37Cl]+, 35), 400([M, 35Cl]+, 100), 369 (12), 304 (11), 291 (10), 290 (13), 289 
(28), 277 (12), 276 (31). HRMS (EI, 70 eV) calcd. for C26H21O2Cl [M, 
35Cl]+: 400.12246; 
found: 400.12207; calcd. for C26H21O2Cl [M, 
37Cl]+: 402.11951; found: 402.12002.  
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Synthesis of 4,7-Bis-(trifluoromethylsulfonyloxy)-chromen-2-on (14)  
 To a CH2Cl2 solution (50 mL) of 13 (1.0 g, 5.6 mmol) was added 
pyridine (1.8 mL, 22.4 mmol) and the solution was stirred at 20 °C for 
10 min under argon atmosphere. Then Tf2O (2.3 mL, 13.5 mmol) was 
added at 20 °C and the reaction mixture was heated at 50 °C for 20 
min. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The product 
14 was isolated by column chromatography (flash silica gel, heptane/EtOAc) as a colourless 
solid (2.1 g, 85 %); mp 79-77 oC. 1H NMR (300 MHz. CDCl3): δ =  6.51 (s, 1H, CH=CH), 7.27-
7.32 (m, 2H, ArH), 7.74 (d, J = 8.7 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 105.6, 
110.1, 111.6 (CH), 112.9 (C), 118.3 (q, JC,F = 320.0 Hz, CF3), 118.6 (q, JF,C = 320.0 Hz, CF3), 
123.6 (CH), 151.4, 152.0, 154.9 (C), 157.3 (C=O). 19F NMR (282.4, MHz): δ = -72.5, -72.4. IR 
(KBr, cm-1):  v = 3171, 2988 (w), 1755 (s), 1698, 1643 (w), 1577 (m), 1550, 1499, 1475, 1433 
(w). GC-MS (EI, 70 eV): m/z (%) = 441 ([M]+, 100), 356 (15), 276 (33), 234(23), 195 (16), 
168 (17). HRMS (EI, 70 eV) calcd. for C11H4O8F6S2 [M]
+: 441.93145; found: 441.93087. 
 
General procedure for the synthesis of (15a-e) 
A solution of 14 (0.045 mmol), K2CO3 (2M, 2 mL), Pd(PPh3)4 (6 mol %) and arylboronic acid 
(2.4 equiv.) in 1,4-dioxane (3 mL) was stirred at 110 °C for 8 h under argon atmosphere. To the 
reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the aqueous 
layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried over (Na2SO4), filtered and the filtrate was concentrated in vacuo. 
The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
4,7-Bis(3,5-dimethylphenyl)-chromen-2on (15a) 
 Starting with 14 (20 mg, 0.045 mmol), 4a (16 mg, 0.11 mmol), 
Pd(PPh3)4 (3 mg, 6 mole%), K2CO3 (2M, 2 mL) and 1,4-dioxane 
(3 mL), 15a was isolated as a white solid (13 mg, 81 %); mp: 127-
130 °C. 1H NMR (300 MHz, CDCl3): δ =2.33 (s, 6H, 2CH3), 2.34 
(s, 6H, 2CH3), 6.27 (s, 1H, ArH), 6.99-7.02 (m, 4H, ArH), 7.09 
(s, 1H, ArH), 7.37-7.40 (m, 1H, ArH), 7.46-7.50 (m, 2H, ArH), 
7.52-7.53 (m, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 21.3 
(2CH3), 21.4 (2CH3), 114.3, 115.3 (CH), 117.9 (C), 122.9, 125.1, 126.2, 127.3, 130.2, 131.2 
(CH), 135.3, 138.5, 138.6, 139.1, 145.2, 154.5, 155.8 (C), 161.0 (C=O). IR (KBr, cm-1): v = 
3356, 3312, 2961, 1943 (m), 1902, 1831, 1805 (s), 1778, 1709 (w), 1688 (m), 1583, 1550, 1470 
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(s), 1419, 1352, 1315 (w), 1255, 1221, 1218 (s), 1157, 1144, 1103 (m). GC-MS (EI, 70 eV): 
m/z (%) = 354 ([M]+, 100), 340 (10), 339 (40), 327 (15), 326 (60), 162 (12). HRMS (EI, 70 eV) 
calcd. for C25H22O2 [M]
+: 354.16143; found: 354.16190. 
 
4,7-Bis(4-methoxyphenyl)-chromen-2-on (15b) 
 Starting with 14 (20 mg, 0.045 mmol), 4e (17 mg, 0.11 
mmol), Pd(PPh3)4 (3 mg, 6 mole%), K2CO3 (2M, 2 mL) and 
1,4-dioxane (3 mL), 15b was isolated as a white solid (11 mg, 
68 %); mp: 112-115 °C. 1H NMR (300 MHz, CDCl3): δ = 3.80 
(s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.26 (s, 1H, CH), 6.95 (d, 
J = 8.9 Hz, 2H, ArH), 6.99 (d, J = 8.9 Hz, 2H, ArH), 7.35-7.39 
(m, 3H, ArH), 7.50-7.54 (m, 4H, ArH). 13C NMR (62.9 MHz, 
CDCl3): δ = 55.4, 55.7 (2OCH3), 110.3, 112.4, 113.0, 114.6 (CH), 117.8 (C), 122.4, 124.4, 
127.6, 128.2 (CH), 131.7, 138.2, 143.2, 155.5, 156.9, 157.8, 159.7 (C), 161.0 (C=O). IR (KBr, 
cm-1): v = 3377 (m), 3012, 2961, 1921, 1850 (w), 1721, 1605 (s), 1578, 1529, 1510 (m), 1463, 
1450, 1440, 1419, 1372, 1309 (w), 1295, 1278 (m), 1257, 1244 (s), 1197, 1179, 1164, 1131, 
1110 (m), 1094 (w). GC-MS (EI, 70 eV): m/z (%) = 358 ([M]+, 100), 331 (10), 330 (43), 315 
(30). HRMS (EI, 70 eV) calcd. for C23H18O4 [M]
+: 358.11996; found: 358.11953. 
 
4,7-Bis(4-ethoxyphenyl)-chromen-2-on (15c) 
Starting with 14 (20 mg, 0.045 mmol), 4g (18 mg, 0.11 
mmol), Pd(PPh3)4 (3 mg, 6 mole%), K2CO3 (2M, 2 mL) and 
1,4-dioxane (3 mL), 15c was isolated as a white solid (12 
mg, 66 %); mp 114-117 °C. 1H NMR (300 MHz. CDCl3): 
δ = 1.36-1.43 ( m, 6H, 2CH3), 3.99-4.09 (m, 4H, 2OCH2), 
6.25 (s, 1H, CH), 6.91-6.99 (m, 4H, ArH), 7.37 (d, J = 8.7 
Hz, 3H, ArH), 7.49-7.59 (m, 4H, ArH). 13C NMR (62.9 
MHz, CDCl3): δ = 14.8 (2CH3), 63.6, 63.7 (2OCH2), 113.7, 
114.7, 114.8, 115.1 (CH), 117.5 (C), 122.4, 127.3 (CH), 127.4 (C), 128.3, 129.9 (CH), 131.2, 
144.6, 154.8, 155.2, 159.6, 160.3 (C), 162.2 (C=O). IR (KBr, cm-1): v = 3051, 3037, 2990, 2972, 
2928, 2894, 2850 (w), 1722, 1605 (s), 1576, 1569 (w), 1510 (m), 1476, 1455 (w), 1436 (m), 
1397, 1386 (w), 1370 (m), 1308 (w), 1295 (m), 1257, 1242 (s). GC-MS (EI, 70 eV): m/z (%) = 
386 ([M]+, 100), 358 (16), 330 (16), 329 (10), 302 (19), 273 (10). HRMS (EI, 70 eV) calcd. for 
C25H22O4 [M]
+: 386.15126; found: 386.15104. 
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4,7-Bis(phenyl)-chromen-2-on (15d) 
 Starting with 14 (20 mg, 0.045 mmol), 4k (13 mg, 0.11 mmol), 
Pd(PPh3)4 (3 mg, 6 mole%), K2CO3 (2M, 2mL) and 1,4-dioxane (3 
mL), 15d was isolated as a white solid (11 mg, 79 %); mp 131-133 
°C. 1H NMR (300 MHz, CDCl3): δ = 6.31 (s, 1H, CH), 7.34-7.37 
(m, 1H, ArH), 7.39-7.44 (m, 5H, ArH), 7.47-7.49 (m, 4H, ArH), 
7.56-7.58 (m, 3H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 113.8, 
114.4 (CH), 116.8 (C), 121.9, 126.2, 126.3 (CH), 126.5 (C), 127.4, 127.6, 127.9, 128.1, 128,7 
(CH), 134.3, 138.0, 144.1, 153.6 (C), 162.1 (C=O). IR (KBr, cm-1): v = 3399, 3070, 3051, 2959, 
2918, 2849, 1722, 1707, 1650, 1631, 1593 (w), 1573, 1535 (m), 1512, 1495 (w), 1446, 1428, 
1402 (m), 1315, 1290 (w), 1285 (s), 1227 (w), 1163, 1156 (m), 1123, 1076, 1012 (s). GC-MS 
(EI, 70 eV): m/z (%) = 298 ([M]+, 100), 297 (17), 271 (20), 241(28), 240 (11), 239 (32). HRMS 
(EI, 70 eV) calcd. for C21H14O2 [M]
+: 298.09883; found: 298.09803. 
 
4,7-Bis(3,5-dimethoxyphenyl)-chromen-2-on (15e) 
Starting with 14 (20 mg, 0.045 mmol), 4l (18 mg, 0.11 
mmol), Pd(PPh3)4 (3 mg, 6 mole%), K2CO3 (2M, 2 mL) and 
1,4-dioxane (3 mL), 15e was isolated as a white solid (13 
mg, 69 %); mp 111-114 °C. 1H NMR (300 MHz. CDCl3): δ 
= 3.02 (s, 6H, 2OCH3), 3.04 (s, 6H, 2OCH3), 5.56 (s, 1H, 
CH), 5.70 (s, 1H, ArH), 5.75-5.79 (m, 3H, ArH), 5.92-5.93 
(m, 2H, ArH), 6.60-6.63 (m, 1H, ArH), 7.76-7.78 (m, 2H, 
ArH). 13C NMR (62.9 MHz, CDCl3): δ = 53.4 (2OCH3), 55.5 (2OCH3), 99.9, 100.5, 101.4, 
105.4, 110.7, 116.6, 122.6 (CH), 123.8 (C), 130.0 (CH), 132.5, 135.7, 150.2, 156.4, 157.5, 
160.5, 160.9 (C), 161.2 (C=O). IR (KBr, cm-1): v = 3377 (m), 3012, 2961, 1921, 1850 (w), 
1721, 1605 (s), 1578, 1529, 1510 (m), 1463, 1450, 1440, 1419, 1372, 1309 (w), 1295, 1278 
(m), 1257, 1244 (s), 1197, 1179, 1164, 1131, 1110 (m), 1094 (w). GC-MS (EI, 70 eV): m/z (%) 
= 418 ([M]+, 100), 390 (28), 369 (13). HRMS (EI, 70 eV) calcd. for  C25H22O6 [M]
+: 418.14313; 
found: 418.14202. 
 
 
 
 
 
Expermental Section 
 
58 
 
General procedure for the synthesis of 16a-h 
A solution of 14 (0.045 mmol), K2CO3 (2M, 2 mL), Pd(PPh3)4 (3 mole%) and arylboronic acid  
(1.0 equiv.) in toluene (3 mL) was stirred at 65 °C. for 6 h. under argon atmosphere. To the 
reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the aqueous 
layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried over (Na2SO4), filtered and the filtrate was concentrated in vacuo. 
The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
4-(3,5-Methylphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16a)  
 Starting with  14 (20 mg, 0.045 mmol), 4a (7 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16a was isolated as a white solid (15 mg, 82 %); mp 93-96 °C. 1H 
NMR (300 MHz, CDCl3): δ = 2.43 (s, 6H, 2CH3),  6.33 (s, 1H, CH), 
6.96 (s, 2H, ArH), 7.07-7.11 (m, 2H, ArH), 7.26-6.27 (m, 1H, ArH), 
7.55 (d, J = 8.9 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -72.51. 13C NMR (62.9 MHz, 
CDCl3): δ =  21.3 (2CH3), 110.6, 115.6, 117.3 (CH), 118.1 (q, JC,F = 320.6 Hz, CF3), 119.3 (C), 
125.9, 128.9, 131.7 (CH), 134.3, 150.7, 154.6, 154.9, 159.9 (C), 161.8 (C=O). IR (KBr, cm-1): 
v = 3085, 3059, 3028, 2956 (w), 2921 (m), 2852 (w), 1650, 1624, 1600 (s), 1545 (m), 1488 (w), 
1444 (m), 1428, 1412, 1400, 1376 (s), 1317 (m), 1269 (w), 1247, 1226 (m), 1204, 1190 (s), 
1160 (m), 1141 (s), 1087, 1075, 1052 (w). GC-MS (EI, 70 eV): m/z (%) = 398 ([M]+, 100), 397 
(16), 384 (19), 265 (14), 250 (11), 238 (11), 237 (65), 209 (48), 181 (12), 166 (32), 165 (45), 
152 (10). HRMS (EI, 70 eV) calcd. for C18H13O5F3S [M]
+: 398.04303; found: 398.04260. 
 
4-(Ethylphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16b)  
Starting with  14 (20 mg, 0.045 mmol), 4d (7 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2  mL), and toluene (3 mL), 
16b was isolated as a white solid (13 mg, 73 %); mp 81-84 °C. 1H 
NMR (300 MHz. CDCl3): δ = 1.24 (t, J = 7.5 Hz, 3H, CH3), 2.69 (q, J 
= 7.4 Hz, 2H, CH2), 6.35 (s, 1H, CH), 7.09 (d, J = 8.5 Hz, 1H, ArH), 
7.19 (s, 1H, ArH), 7.30 (s, 4H, ArH), 7.58 (d, J = 9.0 Hz, 1H, ArH).  
19F NMR (282.4, MHz): δ = -72.52. 13C NMR (62.9 MHz, CDCl3): δ = 15.7 (CH3), 28.7 (CH2), 
110.7, 115.1, 115.3, 117.2 (CH), 118.6 (q, JC,F = 321.2 Hz, CF3), 119.3, 126.4 (C), 128.9, 129.9 
(CH), 150.8, 154.3, 154.8, 159.7 (C), 160.6 (C=O). IR (KBr, cm-1): v = 3371 (m), 3124, 3081, 
3025, 3006, 2968, 2919, 2880, 2850 (w), 1715, 1606 (s), 1555, 1509, 1507, 1489, 1416 (w), 
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1424, 1412 (s), 1361 (m), 1331, 1318 (w), 1238, 1206, 1186 (s), 1155 (w), 1135, 1101, 1017 
(s). GC-MS (EI, 70 eV): m/z (%) = 398 ([M]+, 97), 370 (15), 369 (52), 265 (13), 238 (16),  237 
(100), 209 (31), 181 (18), 166 (10), 153 (35). HRMS (EI, 70 eV) calcd. for C18H13F3O5S [M]
+: 
398.04303; found: 398.04292. 
 
4-(Methoxyphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16c)  
 Starting with  14 (20 mg, 0.045 mmol), 4e (7 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16c was isolated as a white solid (13 mg, 71 %); mp 86-88 °C. 1H 
NMR (300 MHz, CDCl3): δ = 3.83 (s, 3H, OCH3), 6.33 (s, 1H, CH), 
6.95 (d, J = 8.7 Hz, 2H, ArH), 7.10 (dd, J = 8.9, 2,3 Hz, 1H, ArH), 
7.24 (d, J = 2.3 Hz, 1H, ArH), 7.33 (d, J = 8.7  Hz, 2H, ArH), 7.59 (d, 
J = 8.9 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -72.5. 13C NMR (62.9 MHz, CDCl3): δ = 
55.51 (OCH3), 110.8, 114.3, 114.6, 117.3 (CH), 118.3 (q, JC,F = 320.0 Hz, CF3), 119.3, 126.6 
(C), 128.9, 129.9 (CH), 150.6, 153.0, 154.8, 159.7 (C), 161.2 (C=O). IR (KBr, cm-1): v = 3039, 
2967, 2929 (w), 1756, 1699 (s), 1651, 1645, 1596 (s), 1577, 1538, 1519, 1503, 1474, 1453 (w), 
1435 (m), 1396, 1378, 1353 (m), 1295, 1259, 1243, 1209, 1196 (w), 1136 (m), 1084, 1072, 
1029, 999 (w), 960 (m), 907 (w), 868, 848, 816, 777 (m), 760 (s), 731 (w), 705, 692 (s), 676, 
630, 618, 565, 553, 546 (w). GC-MS (EI, 70 eV): m/z (%) = 400 ([M]+, 100), 240 (15), 211 
(33), 183 (23), 168 (19). HRMS (EI, 70 eV) calcd. for C17H11O6F3S [M]
+: 400.02197; found: 
400.02229. 
 
4-(Methylphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16d)  
 Starting with  14 (20 mg, 0.045 mmol), 4f (6 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16d was isolated as a white solid (12 mg, 70 %); mp 79-82 °C. 1H 
NMR (300 MHz, CDCl3): δ = 2.13 (s, 3H, CH3), 6.31 (s, 1H, CH), 
6.99 (d, J = 8.7 Hz, 2H, ArH), 7.08 (dd, J = 8.9, 2,3 Hz, 1H, ArH), 
7.27 (d, J = 2.5 Hz, 1H, ArH), 7.33 (d, J = 8.7  Hz, 2H, ArH), 7.59 (d, 
J = 8.9 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -72.5. 13C NMR (62.9 MHz, CDCl3): δ = 
21.2 (CH3), 110.8, 114.3, 115.8, 117.6 (CH), 118.3 (q, JC,F = 320.3 Hz, CF3), 119.5, 125.6 (C), 
128.3, 129.0 (CH), 150.8, 152.8, 155.8, 159.7 (C), 163.4 (C=O). IR (KBr, cm-1): v = 3139, 
2867, 2729 (w), 1756, 1699, 1675, 1596 (s), 1557, 1528, 1512, 1503, 1484, 1453 (w), 1405, 
1396, 1378, 1353 (m), 1265, 1239, 1213, 1209, 1156 (w), 1112 (m), 1084, 1072 (s), 1009, 980, 
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960 (m), 907 (w), 888, 854, 832 (m), 777, 760 (s), 731 (w), 705, 692 (s), 696, 640, 607, 553, 
546 (w). GC-MS (EI, 70 eV): m/z (%) = 384 ([M]+, 100), 335 (17), 295 (22), 265 (17), 237 
(17), 152 (15). HRMS (EI, 70 eV) calcd. for C17H11O5F3S [M]
+: 384.03225; found: 384.0342.  
 
4-(Ethoxyphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16e) 
 Starting with  14 (20 mg, 0.045 mmol), 4g (8 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16e was isolated as a white solid (15 mg, 78 %); mp 88-91 °C. 1H 
NMR (300 MHz. CDCl3): δ = 1.40 (t, J = 7.0 Hz, 3H, CH3), 4.05 (q, J 
= 7.1 Hz, 2H, OCH2), 6.33 (s, 1H, CH), 6.95-7.00 (m, 2H, ArH), 7.10 
(dd, J = 8.9 , 2.5 Hz, 1H, ArH), 7.27 (s, 1H, ArH), 7.30-7.33 (m, 2H, 
ArH), 7.61 (d, J = 8.9 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -
72.54. 13C NMR (62.9 MHz, CDCl3): δ = 14.8 (CH3), 63.8 (OCH2), 110.7, 115.1, 115.3, 117.2 
(CH), 117.9 (q, JC,F = 321.1 Hz, CF3), 119.3, 126.4 (C), 128.9, 129.8 (CH), 150.8, 154.3, 154.8, 
159.7 (C), 160.6 (C=O). IR (KBr, cm-1): v = 3069, 3052, 2977, 2958, 2924, 2872 (s), 1692, 
1679, 1666, 1649, 1642 (w), 1606 (m), 1573, 1565 (m), 1553 (w), 1512 (m), 1475 (w), 1428 
(s), 1394 (w), 1366 (m), 1293 (w), 1261 (m), 1243, 1214, 1199, 1179, 1140, 1107 (s). GC-MS 
(EI, 70 eV): m/z (%) = 414 ([M]+, 100), 386 (13), 225 (52), 197 (22), 169 (19). HRMS (EI, 70 
eV) calcd. for C18H13F3O6S [M]
+: 414.03794; found: 414.03693. 
 
4-(3-Fluorophenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16f)  
 Starting with  14 (20 mg, 0.045 mmol), 4i (6 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16f was isolated as a white solid (11 mg, 64 %); mp 65-68 °C. 1H NMR 
(300 MHz, CDCl3): δ = 5.61 (s, 1H, CH), 6.31-6.39 (m, 3H, ArH), 6.43 
(s, 1H, ArH), 6.53-6.55 (m, 1H, ArH), 6.72-6.75 (m, 2H, ArH). 19F NMR 
(282.4, MHz): δ = -111.34, -73.14. 13C NMR (62.9 MHz, CDCl3): δ = 110.9 (CH), 115.7 (d, 
JC,F = 23 Hz, CH), 116.3 (CH), 117.3 (d, JC,F = 21 Hz, CH), 117.6 (CH), 118.3 (q, JC,F = 321.1 
Hz, CF3), 124.1 (d, JC,F = 3.3 Hz, CH), 128.5 (CH), 131.1 (d, JC,F = 8 Hz, CH), 136.4 (d, JC,F = 
7.7 Hz, CF), 151.0, 153.1 (C), 153.2 (d, JC,F = 1.0 Hz, CF), 154.7 (C), 159.1 (C=O), 164.4 (d, 
JC,F = 249 Hz, CF). IR (KBr, cm
-1): v = 3086, 3062, 2957, 2918, 2849 (w), 1711, 1605 (s), 
1584, 1563, 1483 (m), 1411 (s), 1371 (m), 1326, 1307, 1278, 1255 (w), 1239, 1200 (s), 1161 
(m), 1136, 1125, 1110 (s), 1079 (m), 990, 978, 859 (s). GC-MS (EI, 70 eV): m/z (%) = GC-MS 
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(EI, 70 eV): m/z (%) = 388 ([M]+, 100), 296 (24), 228 (14), 225 (25), 199 (43). HRMS (EI, 70 
eV) calcd. for C16H8O5F4S [M]
+: 388.00231; found: 388.00187. 
 
4-(Trifluoromethoxyphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16g) 
 Starting with  14 (20 mg, 0.045 mmol), 4m (9 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 mL), 
16g was isolated as a white solid (13 mg, 65 %); mp 61-64 °C. 1H 
NMR (300 MHz, CDCl3): δ = 6.37 (s, 1H, ArH), 7.10-7.14 (m, 1H,  
ArH), 7.29-7.30 (m, 1H, ArH), 7.34 (d, J = 8.12 Hz, 2H, ArH), 7.41-
7.49 (m, 3H, ArH). 19F NMR (282.4, MHz): δ = -72.52, -57.74. 13C 
NMR (62.9 MHz, CDCl3): δ = 109.9, 115.4, 116.5 (CH), 117.8 (C), 118.8 (q, JC,F = 320.4 Hz, 
CF3), 120.5 (CH), 123.4 (q, JC,F  = 259 Hz, CF),  127.5, 129.0 (CH), 149.4 (q,  JC,F  = 2 Hz, CF), 
150.0, 152.1, 153.7 (C), 158.1 (C=O). IR (KBr, cm-1): v = 3102, 2961, 2923, 2851 (w), 1739 
(s), 1620 (m), 1608 (s), 1565, 1507 (m), 1493 (w), 1425 (s), 1411, 1367 (m), 1323 (w), 1256, 
1235, 1198, 1162, 1137, 1099, 1028, 987 (s). GC-MS (EI, 70 eV): m/z (%) = 454 ([M]+, 86), 
362 (21), 321 (18), 294 (17), 293 (100), 237 (25), 152 (23). (ESI-TOF/MS) calcd. for 
C17H9F6O6S [M+H]
+: 455.00185; found: 455.00181.  
 
4-(2, 3, 4-Trimethoxyphenyl)-7-(trifluoromethylsulfonyloxy)-chromen-2-on (16h) 
 Starting with 14 (20 mg, 0.045 mmol), 4n (10 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL), and toluene (3 
mL), 16h was isolated as a white solid (14 mg, 67 %), mp: 97-100 
°C. 1H NMR (300 MHz. CDCl3): δ = 3.68 (s, 3H, OCH3), 3.87 (s, 
6H, 2OCH3), 6.34 (s, 1H, CH), 6.72 (d, J = 8.5 Hz, 1H, ArH), 6.85-
6.87 (m, 1H, ArH), 7.05 (dd, J = 8.9, 2.5 Hz, 1H, ArH), 7.53-7.66 
(m, 2H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -72.06. 13C NMR (62.9 MHz, CDCl3): δ = 
56.9 (OCH3), 61.0, 61.5 (2OCH3), 107.6, 116.7 (CH), 117.1 (C), 118.3 (q, JC,F = 321.1 Hz, 
CF3), 121.0, 122.9 (C), 124.2, 128.5, 129.2, 132.1 (CH), 142.4, 150.6, 152.4, 154.2, 155.4 (C), 
159.7 (C=O). IR (KBr, cm-1): v = 3075, 2917, 2848 (w), 1733 (s), 1607 (w), 1573, 1539, 1494, 
1463 (w), 1414 (m), 1369, 1325, 1296, 1259 (w), 1237, 1209, 1137 (m), 1095 (s). GC-MS (EI, 
70 eV): m/z (%) = 460 ([M]+, 100), 355 (10), 281 (10), 207 (11), 165 (13), 139 (71), 137 (21), 
135 (13). HRMS (EI, 70 eV) calcd. for C19H15O8F3S [M]
+: 460.04342;  found 460.04260.  
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4-(Methoxyphenyl)-7-(methylphenyl)-chromen-2-on (17)  
Starting with 14 (20 mg, 0.045 mmol), 4e (7 mg, 0.045 mmol), 
Pd(PPh3)4 (1.5 mg, 3 mole%), K2CO3 (2M, 2 mL) and toluene (3 
mL), and 4f (7 mg, 0.054 mmol), Pd(PPh3)4 (3 mg, 6 mole%), 
K2CO3 (2M, 2 mL) and 1,4-dioxane (2 mL), 17 was isolated as a 
white solid (13 mg, 84%); mp 104-107 °C. 1H NMR (300 MHz, 
CDCl3): δ = 2.38 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 6.28 (s, 1H, 
C=CH), 7.01 (d, J = 8.7 Hz, 2H, ArH), 7.28 -7.33 (m, 1H, ArH), 
7.37-7.41 (m, 6H, ArH), 7.53 (d, J = 8.00 Hz, 2H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 
21.3 (CH3), 55.5 (OCH3), 114.2 (C), 114.4, 115.5 (CH), 118.0 (C), 122.9, 124.4 (CH), 127.6 
(C), 127.9, 129.0, 129.3, 129.9 (CH), 138.8, 145.2, 152.5, 154.7, 155.2 (C), 161.2 (C=O). IR 
(KBr, cm-1): v = 3012, 2878, 2822 (w), 1966, 1844 (s), 1744, 1696 (m), 1601, 1578, 1522, 1504 
(w), 1487, 1454, 1412 (m). GC-MS (EI, 70 eV): m/z (%) = 342 ([M]+, 100), 318 (23), 280 (16), 
234 (10), 187 (19). HRMS (EI, 70 eV) calcd. for C23H18O3 [M]
+: 342.12505; found: 342.12459. 
 
5-Bromo-quinolin-8-yl trifluoromethanesulfonate (19)  
 To a CH2Cl2 solution (20 mL) of 18 (1.0 g, 4.5 mmol) was added pyridine (0.45 
mL, 5.4 mmol) and the solution was stirred at 20 °C for 10 min under argon 
atmosphere. Then Tf2O (0.9 mL, 5.4 mmol) 2 was added at 20 °C and the reaction 
mixture was heated at 50 °C for 20 min. The reaction mixture was filtered and 
the filtrate was concentrated in vacuo. The product 19 was isolated by column 
chromatography (flash silica gel, heptanes/EtOAc) as a colourless solid (1.35 g, 85%); mp 89-
91 °C. 1H NMR (300 MHz, CDCl3): δ = 7.45 (d, J = 8.31 Hz, 1H, ArH), 7.59 (dd, J = 8.59, 
4.25 Hz, 1H, ArH), 7.80 (d, J = 8.31 Hz, 1H, ArH), 8.51 (dd, J = 8.69, 1.51 Hz, 1H, ArH), 9.01 
(dd, J = 4.15, 1.51 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -73.6. 13C NMR (62.9 MHz, 
CDCl3): δ = 118.9 (q, JC,F = 321.3 Hz, CF3 ), 121.4 (CH), 121.8 (C), 123.7 (CH), 129.0 (C), 
129.4, 135.7 (CH), 141.6, 145.6 (C), 152.2 (CH). IR (KBr, cm-1): v = 3171, 2959, 2845 (w), 
1753, 1733 (s), 1666, 1632, 1588 (m), 1541 (s), 1480, 1476, 1422 (w), 1366 (s), 1244, 1198, 
1170 (m), 1085 (s). GC-MS (EI, 70 eV): m/z (%) = 357 ([M, 81Br]+, 31) 355 ([M, 79Br]+, 34), 
304 (28), 283 (51), 239 (100), 198 (11), 173 (14). HRMS (EI, 70 eV): calcd. for 
C10H5BrF3NO3S [M,
 81Br]+: 356.91051; found: 356.90991; calcd. for C10H5BrF3NO3S [M,
 
79Br]+: 354.91256; found: 354.91241.  
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General procedure for the synthesis of 20a-d 
A solution of 19 (0.056 mmol), K2CO3 (2M, 2 mL), Pd(PPh3)4 (6 mmol%) and arylboronic acid  
(2.0 equiv.) in 1,4-dioxane (3 mL) was stirred at 110 °C for 10 h. under argon atmosphere. To 
the reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the 
aqueous layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuum .The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
5,8-Bis(3,5-dimethylphenyl)quinoline  (20a) 
Starting with 19 (20 mg, 0.056 mmol), a4 (17 mg, 0.112 mmol), Pd(PPh3)4 (4 
mg, 6 mole%), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 mL), 20a was isolated 
as a white solid (15 mg, 81 %); mp 105-107 °C. 1H NMR (300 MHz, CDCl3): 
δ = 2.34 (br. s, 12H, 4CH3), 6.98 (br. s, 1H, ArH), 7.04 (br. s, 3H, ArH), 7.21-
7.30 (m, 3H, ArH), 7.44 (d, J = 7.37 Hz, 1H, ArH), 7.64 (d, J = 7.37 Hz, 1H, 
ArH), 8.23 (dd, J = 8.59, 1.79 Hz, 1H, ArH), 8.86 (dd, J = 4.15, 1.70 Hz, 1H, 
ArH ). 13C NMR (62.9 MHz, CDCl3): δ = 20.3, 20.4 (4CH3), 120.7 (CH), 
125.7 (C), 126.7 (CH), 126.9 (C), 127.9, 128.4, 129.1, 129.2, 129.7, 134.7 (CH), 136.3, 136.9, 
138.4, 138.5, 139.1, 145.4 (C), 149.9 (CH). IR (KBr, cm-1): v = 3011, 2955, 2917, 2850, 2730 
(w), 1727, 1683, 1596, 1576, 1500, 1455, 1392 (m), 1373, 1355, 1325, 1290, 1259 (w), 1227, 
1200, 1184, 1167, 1155 (m), 1093, 1035 (s). GC-MS (EI, 70 eV): m/z (%) = 337 ([M]+, 67), 
336 (100), 322 (78), 232 (12). HRMS (ESI-TOF/MS): calcd for C25H24N [M+H]
+: 338.19033 
;found: 338.19043.  
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5,8-Bis(3-methylphenyl)quinoline (20b)  
Starting with 19 (20 mg, 0. 056 mmol), 4b (15 mg, 0.112 mmol), Pd(PPh3)4 (4 
mg, 6 mole%), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 mL), 20b was isolated as 
a white solid (14 mg, 77 %); mp 79-80 °C. 1H NMR (300 MHz, CDCl3): δ = 2.38 
(s, 6H, 2CH3), 7.15-7.24 (m, 3H, ArH), 7.32-7.34 (m, 1H, ArH), 7.39-7.46 (m, 
3H, ArH), 7.56-7.60 (m, 2H, ArH), 7.80 (d, J = 8.3 Hz, 1H, ArH), 8.19 (dd, J  = 
8.7, 1.7 Hz, 1H, ArH), 8.51 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 8.99 (dd, J = 4.72, 
1.7 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 20.3 (2CH3), 120.3, 121.4 
(CH), 121.8 (C), 123.7, 126.2, 127.0 (CH), 128.2 (C), 128.5, 129.0, 129.4, 130.6, 134.6, 135.7 
(CH), 137.9, 138.5, 141.1, 141.4, 145.2, 145.6 (C), 151.3, 152.2 (CH). IR (KBr, cm-1): v = 
3042, 2956, 2924, 2854 (w), 1727, 1593 (m), 1573, 1562 (w), 1499, 1491, 1463 (m), 1422 (s), 
1382, 1352, 1308, 1293 (w), 1246 (m), 1205, 1138 (s). GC-MS (EI, 70 eV): m/z (%) = 309 
([M]+,54), 289 (81), 247 (100),  211 (21), 177 (18), 163 (09). HRMS (ESI-TOF/MS): calcd for 
C23H20N [M+H]
+: 310. 15175; found: 310.15139.  
 
5,8-Bis(p-methoxyphenyl)quinoline (20c)  
Starting with 19 (20 mg, 0.056 mmol), 4e (17 mg, 0.112 mmol), Pd(PPh3)4 (4 
mg, 6 mole%), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 mL), 20c was isolated as 
a white solid (13 mg, 68 %); mp 119-120 °C. 1H NMR (300 MHz, CDCl3): δ = 
3.82 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.99 (br. d, J = 8.5 Hz, 4H, ArH), 7.28 
(dd, J = 8.7, 4.2 Hz, 1H, ArH), 7.36 (d, J = 8.9 Hz, 2H, ArH), 7.45 (d, J = 7.6 
Hz, 1H, ArH), 7.62 (d, J = 8.9 Hz, 2H, ArH), 7.67 (d, J = 7.4 Hz, 1H, ArH), 8.23 
(dd, J = 8.6, 1.8 Hz, 1H, ArH), 8.88 (dd, J = 4.2, 1.7 Hz, 1H, ArH). 13C NMR 
(62.9 MHz, CDCl3): δ = 55.3, 55.4 (OCH3), 113.6, 113.9, 120.7, 126.9 (CH), 
127.3 (C), 129.5, 131.1, 131.7 (CH), 131.9, 132.0 (C), 134.6 (CH), 139.3, 139.4, 
146.3 (C), 149.8 (CH), 159.1, 159.3 (C). IR (KBr, cm-1): v = 2989 (w), 2967, 2855, 2821 (m), 
1788, 1756 (s), 1689, 1644, 1632, 1619, 1589, 1576 (w), 1512 (s), 1477, 1435, 1412, 1344, 
1312 (m), 1298, 1276, 1254 (s), 1176, 1144, 1132, 1117, 1098 (m). GC-MS (EI, 70 eV): m/z 
(%) = 341 ([M]+, 86), 340 (100), 326 (16), 297 (7), 254 (10), 234 (11). HRMS (ESI-TOF/MS): 
calcd for C23H20NO2 [M+H]
+: 342.14886; found: 342.14897. 
 
 
 
 
Expermental Section 
 
65 
 
5,8-Bis(p-ethoxyphenyl)quinoline (20d)  
Starting with  19 (20 mg, 0.056 mmol), 4g (19 mg, 0.112 mmol), Pd(PPh3)4 
(4 mg, 6 mole%), K2CO3 (2M, 2 mL) and 1,4-dioxane (3 mL), 20d was 
isolated as a white solid (15 mg, 72 %); mp 127-129 °C. 1H NMR (300 MHz, 
CDCl3): δ = 1.37-1.44 (m, 6H, 2CH3), 4.02-4.10 (m, 4H, 2OCH2), 6.96-6.99 
(m, 4H, ArH), 7.27 (dd, J = 8.6, 4.1 Hz, 1H, ArH), 7.34 (d, J = 7.8 Hz, 2H, 
ArH), 7.45 (d, J = 7.3 Hz, 1H, ArH), 7.6 (d, J = 8.7 Hz, 2H, ArH), 7.67 (d, J 
= 7.3 Hz, 1H, ArH), 8.24 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 8.87 (dd, J = 4.2, 
1.7 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): δ = 28.6, 29.9 (2CH3), 62.4, 
62.5 (2OCH2), 113.1, 113.4, 119.6, 125.9 (CH), 126.2 (C), 128.4, 130.1, 
130.7 (CH), 130.8 (C), 133.6 (CH), 138.2, 128.4, 142.3, 145.2 (C), 148.7 
(CH), 157.4, 157.5 (C). IR (KBr, cm-1): v = 3041, 2957 (w), 2885, 2842 (m), 
1713 (s), 1574 (m), 1512 (s), 1490 (w), 1472 (m), 1431, 1410 (w), 1299, 1282 (m), 1258 (w), 
1239 (s), 1175 (m), 1151, 1131 (w), 1110. 1098 (m). GC-MS (EI, 70 eV): m/z (%) = 369 ([M]+, 
100), 368 (98), 341 (10), 340 (45), 312 (11), 283 (11), 282 (14). HRMS (ESI-TOF/MS): calcd 
for C25H24NO2 [M+H]
+: 370.18016; found: 370.18022   
 
General procedure for the synthesis of 21a-h 
A solution of 19 (0.056 mmol), K3PO3 (1.0 equiv.), Pd(PPh3)4 (3 mmol%) and arylboronic acid  
(1.0 equiv.) in toluene (3 mL) was stirred at 85 °C for 9 h under argon atmosphere. To the 
reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the aqueous 
layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
 
 
 
 
 
 
 
 
 
Expermental Section 
 
66 
 
5-(3,5-Methylphenyl)-quinolin-8-yl trifluoromethanesulfonate  (21a) 
Starting with 19 (20 mg, 0.056 mmol), 4a (8 mg, 0.056 mmol), Pd(PPh3)4 (2 
mg, 3 mole%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 
21a was isolated as a white solid (16 mg, 76 %); mp 97-99 °C.  1H NMR (300 
MHz, CDCl3): δ = 2.35 (s, 6H, 2CH3), 6.98 (br. s, 2H, ArH), 7.05 (br. s, 1H, 
ArH), 7.39-7.43 (m, 2H, ArH), 7.57 (d, J = 7.9 Hz, 1H, ArH), 8.21 (dd, J = 
8.69, 1.70 Hz, 1H, ArH), 8.98 (dd, J = 4.15, 1.51 Hz, 1H, ArH). 19F NMR 
(282.4, MHz): δ = -73.7. 13C NMR (62.9 MHz, CDCl3): δ = 20.3 (2CH3), 118.3 (q, JC,F = 320.8 
Hz, CF3), 119.3, 121.4, 125.2 (CH), 126.5 (C), 126.7, 128.8 (CH), 132.3 (C), 133.7 (CH), 136.9, 
137.3, 140.1, 140.6 (C), 150.2 (CH). IR (KBr, cm-1): v = 2961 (m), 2922, 2853, 1594, 1499 (w), 
1423 (m), 1257 (s), 1222, 1209 (w), 1078 (m), 1008 (s). GC-MS (EI, 70 eV): m/z (%) = 381 
([M]+, 37), 249 (19), 248 (100),  221 (13), 220 (78), 204 (32). HRMS (EI, 70 eV) calcul for 
C18H14F3NO3S [M]
+: 381.06381; found: 381.06410. 
 
5-(4-Chloro)-quinolin-8-yl trifluoromethanesulfonate (21b)  
Starting with 19 (20 mg, 0.056 mmol), 4c (9 mg, 0.056 mmol), Pd(PPh3)4 (2 mg, 
3 mole%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 21b was 
isolated as a white solid (13 mg, 60 %); mp 143-145 °C.  1H NMR (300 MHz, 
CDCl3): δ = 7.32 (d, J = 8.5 Hz, 2H, ArH), 7.42-7.46 (m, 4H, ArH), 7.59 (d, J = 
7.9 Hz, 1H, ArH), 8.13 (dd, J = 8.7, 1.5 Hz, 1H, ArH), 9.01 (dd, J = 4.5, 1.5 Hz, 
1H, ArH). 19F NMR (282.4, MHz): δ = -73.7. 13C NMR (62.9 MHz, CDCl3): δ = 
119.1 (q, JC,F = 320.4 Hz, CF3), 119.4, 121.6, 126.5 (CH), 127.0 (C), 127.9, 
130.2, 133.2 (CH), 133.6, 135.3, 138.8, 140.2, 146.5 (C), 150.5 (CH). IR (KBr, cm-1): v = 3070, 
3050, 2959, 2929, 2873, 2850 (w), 1731 (m), 1597 (w), 1501, 1467 (m), 1424 (s), 1400, 1309 
(w), 1258, 1243, 1208, 1172 (m), 1139, 1123, 1082, 1043, 1024, 1013 (s). GC-MS (EI, 70 eV): 
m/z (%) = 389 ([M, 37Cl]+, 14), 387( [M, 35Cl]+, 36), 256 (34), 255 (17), 254 (99), 228 (34), 227 
(17), 226 (100). HRMS (EI, 70 eV) calculd for C16H9O3NClF3S ([M, 
35Cl]+): 386.99341; found: 
386.99383; calculd for ([M, 37Cl]+): 388.99088; found: 388.990297. 
 
 
 
 
 
 
Expermental Section 
 
67 
 
 5-(4-Ethylphenyl)-quinolin-8-yl trifluoromethanesulfonate (21c) 
 Starting with 19 (20 mg, 0. 056 mmol), 4d (8 mg, 0.056 mmol), Pd(PPh3)4 (2 
mg, 3 mole%), K3PO4 (1.0 equiv. ) (12 mg, 0.056 mmol), and toluene (3 mL), 
21c was isolated as a white solid (16 mg, 75 %); mp 106-108 °C. 1H NMR (300 
MHz, CDCl3): δ = 1.26 (t, J = 7.5 Hz, 3H, CH3), 2.71 (q, J = 7.6 Hz, 2H, CH2), 
7.29 (br. s, 4H, ArH), 7.39-7.44 (m, 2H, ArH), 7.58 (d, J = 8.2 Hz, 1H, ArH), 
8.22 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 8.99 (dd, J = 4.2, 1.5 Hz, 1H, ArH). 19F 
NMR (282.4, MHz): δ = -73.6. 13C NMR (62.9 MHz, CDCl3): δ = 15.5 (CH3), 
30.9 (CH2), 119.1 (q, JC,F = 320.8 Hz, CF3), 120.4, 122.4, 126.3 (CH), 127.3 (C), 128.2, 129.8, 
134.7 (CH), 135.3, 141.2, 141.4, 144.5, 145.2 (C), 151.3 (CH). IR (KBr, cm-1):  v = 2959 (w), 
2917, 2849 (s), 1736, 1711, 1611, 1592, 1569, 1513, 1495 (w), 1467, 1464 (m), 1421 (s), 1401, 
1382, 1357, 1306, 1260 (w), 1244, 1202 (s), 1170 (m), 1140 (s). GC-MS (EI, 70 eV): m/z (%) 
= 381 ([M]+, 35), 250 (23), 249 (22), 248 (100), 222 (11), 221 (10), 220 (44), 205 (22), 204 
(12), 193 (29). HRMS (EI, 70 eV): calcd. for C18H14F3NO3S [M]
+: 381.06465; found: 
381.06449. 
 
5-(4-Methoxyphenyl)-quinolin-8-yl trifluoromethanesulfonate (21d)  
 Starting with 19 (20 mg, 0.056 mmol), 4e (9 mg, 0.056 mmol), Pd(PPh3)4 (2 mg, 
3 mole%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 21d 
was isolated as a white solid (18 mg, 84 %); mp 108-110 °C. 1H NMR (300 MHz, 
CDCl3): δ = 3.82 (s, 3H, OCH3), 6.99 (d, J = 8.9 Hz, 2H, ArH), 7.39-7.43 (m, 
2H, ArH), 7.45 (d, J = 8.9 Hz, 2H, ArH), 7.57 (d, J = 7.9 Hz, 1H, ArH), 8.21 (dd, 
J = 8.7, 1.7 Hz, 1H, ArH), 8.98 (dd, J = 4.2, 1.5 Hz, 1H, ArH). 19F NMR (282.4, 
MHz): δ = -73.7. 13C NMR (62.9 MHz, CDCl3): δ = 55.4 (OCH3), 114.2 (CH), 
118.5 (q, JC,F = 322.5 Hz, CF3 ), 120.4, 122.4, 126.2 (CH), 131.0 (C), 131.1 (CH), 133.1 (C), 
134.6 (CH), 135.9, 139.2, 143.7 (C), 151.2 (CH), 159.7 (C). IR (KBr, cm-1): v = 3189, 2974, 
2966 (w), 2898, 2876, 2833 (m), 1798 (s), 1783, 1766 (m), 1723, 1693, 1665, 1622 (w), 1584, 
1566 (s), 1532, 1487, 1466 (w), 1411, 1382, 1354, 1334, 1312 (m), 1276 (s), 1273, 1244 (w), 
1212, 1167, 1154, 1134, 1089 (m). GC-MS (EI, 70 eV): m/z (%) = 383 ([M]+, 23),  251 (14), 
250 (100), 222 (63), 179 (20), 178 (22). HRMS (EI, 70 eV): calcd for C17H12F3NO4S [M]
+: 
383.04336; found: 383.04323. 
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5-(p-Tolyl)-quinolin-8-yl trifluoromethanesulfonate (21e) 
 Starting with 19 (20 mg, 0.056 mmol), 4f (8 mg, 0.056 mmol), Pd(PPh3)4 (2 mg, 
3 mole %), K3PO4 (1.0 equiv) (12 mg, 0.056 mmol), and toluene (3 mL), 21e was 
isolated as a white solid (17 mg, 81 %); mp 102-104 °C. 1H NMR (300 MHz, 
CDCl3): δ = 2.40 (s, 3H, CH3), 7.27 (br. s, 4H, ArH), 7.38-7.44 (m, 2H, ArH), 
7.58 (d, J = 7.9 Hz, 1H, ArH), 8.21 (dd, J = 8.6, 1.6 Hz, 1H, ArH), 8.99 (dd, J = 
4.2, 1.5 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -73.7. 13C NMR (62.9 MHz, 
CDCl3): δ = 21.2 (CH3), 117.7 (q, JC,F = 321.5 Hz, CF3), 120.5, 122.3 (CH), 126.2 
(C), 128.2, 129.4, 129.8, 134.5 (CH), 135.1, 138.2, 141.2, 141.3, 145.2 (C), 151.2 (CH). IR 
(KBr, cm-1):  v = 3058, 3018, 2952, 2920, 2850 (w), 1722, 1671, 1587 (m), 1500 (w), 1454, 
1423 (s), 1395, 1379, 1354 (m), 1242, 1208 (s), 1171 (w), 1157, 1139 (m). GC-MS (EI, 70 eV): 
m/z (%) = 367 ([M]+, 37), 235 (16), 234 (100), 207 (15), 206 (88), 205 (10), 204 (28), 191 (11). 
HRMS (EI, 70 eV) calcd for C17H12F3NO3S [M]
+: 367.04845; found: 367.04755. 
 
5-(4-Ethoxyphenyl)-quinolin-8-yl trifluoromethanesulfonate (21f) 
 Starting with 19 (20 mg, 0.056 mmol) 4g (9 mg, 0.056 mmol), Pd(PPh3)4 (4 mg, 
3 mole %), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 21f 
was isolated as a white solid (15 mg, 69 %); mp 113-114 °C.1H NMR (300 MHz, 
CDCl3): δ = 1.41 (t, J = 7.0 Hz, 3H, CH3), 4.06 (q, J = 7.1 Hz, 2H, OCH2), 6.97 
(d, J = 8.7 Hz, 2H, ArH), 7.28 (d, J = 8.9 Hz, 2H, ArH), 7.38-7.42 (m, 2H, ArH), 
7.57 (d, J = 7.9 Hz, 1H, ArH), 8.21 (dd, J = 8.7, 1.70 Hz, 1H, ArH), 8.98 (dd, J 
= 4.2, 1.5 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -73.6. 13C NMR (62.9 MHz, 
CDCl3): δ = 14.8 (CH3), 63.6 (OCH2), 114.7 (CH), 119.2 (q, JC,F = 320.9 Hz, 
CF3 ), 120.4, 122.3, 126.2 (CH), 128.3, 130.1 (C), 131.0, 134.6 (CH), 137.2, 141.0, 144.3 (C), 
151.2 (CH), 159.1 (C). IR (KBr, cm-1): v = 3042, 2994, 2917, 2849 (w), 1606 (s), 1591, 1572 
(w), 1514 (s), 1493, 1475, 1461 (m), 1443 (w), 1420 (s), 1405, 1395, 1381 (m), 1354, 1342 (w), 
1303 (m), 1290, 1255, 1227, 1206, 1179, 1130, 1117, 1083, 1044 (s). GC-MS (EI, 70 eV): m/z 
(%) = 397 ([M]+, 28), 265 (19), 264 (100), 236 (14), 209 (10), 152 (11). HRMS (EI, 70 eV) 
calculd for C18H14F3NO4S [M]
+: 397.05901; found: 397.5842.  
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5-(4-Fluorophenyl)-quinolin-8-yl trifluoromethanesulfonate (21g) 
 Starting with 19 (20 mg, 0.056 mmol), 4o (8 mg, 0.056 mmol), Pd(PPh3)4 (2 mg, 
3 mole%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 21g was 
isolated as a white solid (13 mg, 63 %); mp 134-136 °C. 1H NMR (300 MHz. 
CDCl3): δ = 7.15 (d, J = 8.7 Hz, 2H, ArH), 7.32-7.38 (m, 2H, ArH), 7.41-7.46 
(m, 2H, ArH), 7.59 (d, J = 7.9 Hz, 1H, ArH), 8.14 (dd, J = 8.7, 1.5 Hz, 1H, ArH), 
9.00 (dd, J = 4.2, 1.5 Hz, 1H, ArH). 19F NMR (282.4, MHz): δ = -113.4, -73.8. 
13C NMR (62.9 MHz, CDCl3): δ = 115.8 (d, JC,F =21.5 Hz, CH), 118.6 (q, JC,F = 
321.2 Hz, CF3), 120.4, 122.7, 126.5 (CH), 128.0, 128.2, 130.7 (C), 131.6 (d, JC,F = 8.7 Hz, CH), 
133.9 (C), 134.2 (CH), 145.4 (C), 151.4 (CH), 163.4 (d, JC,F = 245.7 Hz, CF). IR (KBr, cm
-1): 
v = 2955, 2918, 2849, 1738 (w), 1605 (m), 1573 (w), 1511 (s), 1495 (w), 1468 (m), 1420, 1403 
(s), 1381, 1356, 1335, 1309, 1274 (w), 1243, 1225, 1210 (s), 1172, 1165 (m), 1134 (s), 1085 
(m). GC-MS (EI, 70 eV): m/z (%) = 371 ([M]+, 28), 239 (12), 211 (15), 210 (100), 128 (75). 
HRMS (EI, 70 eV) calculd for C16H9O3NF4S [M]
+: 371.02338; found: 371.02351. 
 
5-(2-Methoxyphenyl)-quinolin-8-yl trifluoromethanesulfonate (21h)  
Starting with 19 (20 mg, 0.056 mmol), 4p (9 mg, 0.056 mmol), Pd(PPh3)4 (2 mg, 
3 mole%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL), 21h 
was isolated as a white solid (17 mg, 79 %); mp 85-87 °C. 1H NMR (300 MHz, 
CDCl3): δ = 3.36 (s, 3H, OCH3), 6.98-7.06 (m, 2H, ArH), 7.17-7.21 (m, 1H, 
ArH), 7.34-7.44 (m, 3H, ArH), 7.58 (d, J = 7.9 Hz, 1H, ArH), 7.87 (dd, J = 8.6, 
1.6 Hz, 1H, ArH), 8.96 (dd, J = 4.1, 1.4 Hz, 1H, ArH). 19F NMR (282.4, MHz): 
δ = -72.8. 13C NMR (62.9 MHz, CDCl3): δ = 55.4 (OCH3), 111.0 (CH), 119.3 (q, JC,F = 318.9 
Hz, CF3), 120.4, 120.9, 122.6, 126.5 (CH), 128.0, 128.2, 129.1 (C), 131.5, 131.6 (CH), 133.9 
(C), 135.1 (CH), 145.4 (C), 151.2 (CH), 156.9 (C). IR (KBr, cm-1): v = 3062, 2958, 2918, 2849, 
1931, 1901, 1737, 1618 (w), 1600 (m), 1579 (w), 1502, 1493, 1471, 1435 (m), 1416, 1402 (s), 
1388, 1362, 1312 (w), 1290, 1263 (m), 1236, 1208, 1201 (s), 1173, 1164 (m), 1140, 1121 (s). 
GC-MS (EI, 70 eV): m/z (%) = 383 ([M]+, 53), 251 (18), 250 (100), 222 (20), 220 (10), 206 
(15), 204 (12), 194 (26), 193 (10), 191 (17), 178 (12), 151 (10). HRMS (ESI-TOF/MS): calcd 
for C17H13F3NO4S [M+H]
+: 384.05119; found: 384.05153.  
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5-(p-Methylphenyl)-8-(p-methoxyphenyl)quinoline (22)  
 Starting with 19 (20 mg, 0.056 mmol), 4f (8 mg, 0.056 mmol), Pd(PPh3)4 (2 
mg, 3 mol-%), K3PO4 (1.0 equiv.) (12 mg, 0.056 mmol), and toluene (3 mL) 
and 4e (17 mg, 0.112 mmol), Pd(PPh3)4 (4 mg, 6 mole %), K3PO4 (1.0 equiv.) 
(12 mg, 0.056 mmol) and 1,4-dioxane (3 mL), 22 was isolated as a white solid 
(14 mg, 76%), mp: 118-119 °C.1H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H, 
CH3), 3.84 (s, 3H, OCH3), 6.99 (d, J = 8.5 Hz, 2H, ArH), 7.23-7.29 (m, 3H, 
ArH), 7.36 (d, J = 8.8 Hz, 2H, ArH), 7.46 (d, J = 7.3 Hz, 1H, ArH), 7.56 (d, J 
= 7.9 Hz, 2H, ArH), 7.68 (d, J = 7.3 Hz, 1H, ArH), 8.23 (dd, J = 8.5, 1.9 Hz, 
1H, ArH), 8.87 (dd, J = 4.1, 1.9 Hz, 1H, ArH). 13C NMR (62.9 MHz, CDCl3): 
δ = 20.3 (CH3), 54.4 (OCH3), 112.9, 119.7 (CH), 124.6 (C), 125.9 (CH), 126.2 (C), 127.8, 
128.5, 129.5, 130.2 (CH), 130.5, 130.9 (C), 133.5 (CH), 135.9, 139.5, 139.9 (C), 148.8 (CH), 
158.2 (C). IR (KBr, cm-1): v = 3034, 2973 (w), 2878 (m), 1986, 1964 (s), 1875, 1844, 1776 (m), 
1722, 1702 (w), 1656, 1634, 1612 (m), 1587, 1564, 1532 (w), 1455, 1412 (m), 1376, 1347 (s), 
1289, 1244 (m), 1167, 1133 (w), 1057, 988 (m). GC-MS (EI, 70 eV): m/z (%) = 325 ([M]+, 66), 
324 (100), 310 (20), 281 (11), 266 (10), 218 (11), 140 (10), 133 (24). HRMS (ESI-TOF/MS): 
calculd for C23H19NO [M+H]
+: 326.15394; found: 326.15404.  
 
5,7-Bis(trifluoromethanesulfonyloxy)isoflavone (24) 
To a CH2Cl2 solution (30 mL) of 23 (1.0 g, 3.9 mmol) was added 
pyridine (1.3 mL, 15.7 mmol) and the solution was stirred at 20 
°C for 10 min under argon atmosphere. Then Tf2O (1.6 mL, 9.4 
mmol) was added at 50 °C and the reaction mixture was allowed 
to warm to room temperature and was stirred for 4 h. The reaction mixture was filtered and the 
filtrate was concentrated in vacuo. The product 24 was isolated by column chromatography 
(flash silica gel, heptane/EtOAc) as a colourless solid (1.8 g, 89%); mp 75-77 oC. 1H NMR (300 
MHz, CDCl3): δ = 7.09 (s, 1H, ArH), 7.35-7.39 (m, 3H, ArH), 7.42-7.47 (m, 3H, ArH), 7.92 (s, 
1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.10, -72.19. 13C NMR (75.5 MHz, CDCl3): δ 
= 111.3, 112.3 (CH), 117.3 (C), 117.6 (q, JC,F = 321.9 Hz, CF3), 117.7 (q, JC,F  = 321.9 Hz, CF3), 
126.4 (C), 127.7 (CH), 128.0 (2CH), 128.9, 147.3, 149.7 (C), 151.3 (CH), 156.3 (C), 172.0 
(CO). IR (KBr, cm-1): v = 3095, 2961, 2918, 2849 (w), 1645, 1619 (s), 1578, 1569, 1497, 1469 
(w), 1424 (s), 1377, 1364, 1316 (w), 1243 (m), 1203, 1173, 1137, 1099 (s). GC-MS (EI, 70 
eV): m/z (%) = 518 ([M+H]+, 100), 384 (12), 293 (36), 224 (34). HRMS (EI, 70 eV) calcd. for 
C17H9O8F6S2 [M+H]
+: 518.96375; found: 518.96486.  
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General procedure for the synthesis of 25a-c 
A solution of 24 (0.039 mmol), K2CO3 (2M, 1.5 mL), Pd(PPh3)4 (6 mmol%) and arylboronic 
acid  (2.0 equiv.) in 1,4-dioxane (3 mL) was stirred at 110 °C for 10 h. under argon atmosphere. 
To the reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the 
aqueous layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuum .The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
5,7-Bis(3,5-dimethylphenyl)-3-phenyl-4H-chromen-4-one (25a)  
Starting with 24 (20 mg, 0.039 mmol), 4a (12 mg, 0.078 
mmol), Pd(PPh3)4 (2.7 mg, 6 mole%), K2CO3 (1.5 mL), and 
1,4-dioxane (3 mL), 25a was isolated as a white solid (14 
mg, 87%); mp 111-113 °C. 1H NMR (300 MHz, CDCl3): δ 
= 2.27 (s, 6H, 2CH3), 2.32 (s, 6H, 2CH3), 6.89 (s, 2H, ArH), 
6.92 (s, 1H, ArH), 7.00 (s, 1H, ArH), 7.21-7.31 (m, 5H, 
ArH), 7.34 (d, J = 1.7 Hz, 1H, ArH), 7.42-7.46 (m, 2H, ArH), 
7.59 (d, J =1.9 Hz, 1H, ArH), 7.90 (s, 1H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 21.4 (2CH3), 
21.5 (2CH3), 115.2 (CH), 118.4 (C), 125.2, 126.3, 127.6, 127.9, 128.3, 128.8, 129.2, 130.3 
(CH), 136.2, 138.7, 141.9, 144.4, 145.3, 150.85 (C), 151.8 (CH), 152.9, 154.4, 157.2 (C), 172.2 
(CO). IR (KBr, cm-1): v = 3092, 3053, 3026 (w), 2919, 2850 (m), 2725, 1737, 1710 (w), 1637 
(s), 1619 (m), 1608, 1599 (s), 1553 (m), 1487, 1455, 1445 (w), 1375 (m), 1329, 1312, 1293 
(w), 1259, 1217 (m), 1118, 1083 (w). GC-MS (EI, 70 eV): m/z (%) =429 ([M-H]+, 100), 412 
(12). HRMS (EI, 70 eV) calcd. for C31H25O2 [M-H]
+: 429.18491; found: 429.18478. 
 
5,7-Bis(4-ethylphenyl)-3-phenyl-4H-chromen-4-one (25b)  
Starting with 24 (20 mg, 0.039 mmol), 4d (12 mg, 0.078 
mmol), Pd(PPh3)4 (2.7 mg, 6 mole%), K2CO3 (1.5 mL), 
and 1,4-dioxane (3 mL), 25b was isolated as a white 
solid (13.5 mg, 81%); mp 101-103 °C. 1H NMR (300 
MHz, CDCl3): δ = 1.19-1.24 (m, 6H, 2CH3), 2.60-2.68 
(m, 4H, 2CH2), 7.14-7.18 (m, 2H, ArH), 7.20-7.29 (m, 
7H, ArH), 7.38 (d, J = 1.9 Hz, 1H, ArH), 7.41-7.44 (m, 
2H, ArH), 7.55 (d, J = 8.2 Hz, 2H, ArH), 7.60 (d, J = 1.9 Hz, 1H, ArH), 7.88 (s, 1H, ArH). 13C 
NMR (75.5 MHz, CDCl3): δ = 15.2 (CH3), 15.5 (CH3), 28.6 (CH2), 29.7 (CH2), 115.0 (CH), 
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120.5, 126.4 (C), 127.1, 127.3, 127.6, 127.9, 128.3, 128.6, 128.7, 129.3 (CH), 132.0, 136.0, 
139.1, 142.8, 144.3, 145.1, 145.2 (C), 151.8 (CH), 157.9 (C), 175.9 (CO). IR (KBr, cm-1): v = 
3052, 3024 (w), 2961, 2923, 2869, 2850 (m), 1902, 1789, 1713 (w), 1647, 1605 (s), 1548, 1514, 
1493, 1445 (m), 1423 (w), 1384, 1372, 1360 (s), 1304 (m), 1244 (s), 1187 (m), 1157 (w). GC-
MS (EI, 70 eV): m/z (%) = 429 ([M-H]+ ,100), 431 (11), 414 (8). HRMS (EI, 70 eV) calcd. for 
C31H25O2 [M-H]
+: 429.18491; found: 429.18465. 
 
5,7-Bis(p-tolyl)-3-phenyl-4H-chromen-4-one (25c) 
Starting with 24 (20 mg, 0.039 mmol), 4f (11 mg, 0.078 
mmol), Pd(PPh3)4 (2.7 mg, 6 mole%), K2CO3 (1.5 mL), and 
1,4-dioxane (3 mL), 25c was isolated as a white solid (12 
mg, 76%); mp 107-110 °C. 1H NMR (300 MHz, CDCl3): δ 
= 1.19 (m, 6H, 2CH3), 7.11-7.14 (m, 2H, ArH), 7.18-7.21 
(m, 3H, ArH), 7.24-7.29 (m, 4H, ArH), 7.37 (d, J = 1.9 Hz, 
1H, ArH), 7.41-7.44 (m, 2H, ArH), 7.52 (d, J = 8.1 Hz, 2H,  
ArH), 7.60 (d, J = 1.9 Hz, 1H, ArH), 7.89 (s, 1H, ArH). 13C NMR (75.5 MHz, CDCl3): δ = 29.7 
(2CH3), 115.0 (CH), 115.7 (C), 116.9 (CH), 126.8 (C), 127.2 (CH), 127.5, 128.0 (C), 128.2 
(2CH), 128.3, 128.4, 129.3, 129.9 (CH) 130.1, 130.3, 131.5, 134.8, 141.2, 145.2 (C), 153.1 
(CH), 173.0 (CO). IR (KBr, cm-1): v = 3047, 3025, 2953 (w), 2918 (s), 2850 (m), 1902, 1799, 
1736 (w), 1657 (s), 1621 (m), 1606 (s), 1577, 1549, 1516, 1494, 1461, 1446, 1431, 1418, 1400 
(w), 1375, 1371 (m), 1314, 1306, 1295 (w) 1247, 1239 (w), 1212, 1195, 1185, 1160, 1109, 
1096 (w), 1073 (m), 1045, 1038 (w), 1017 (m). GC-MS (EI, 70 eV): m/z (%) = 401 ([M-H]+, 
100), 402 (48), 403 (10).  HRMS (EI, 70 eV) calcd. for C29H21O2 [M-H]
+: 401.15361; found: 
401.15322.  
 
General procedure for the synthesis of 26a-d 
A solution of 24 (0.039 mmol), K3PO4 (0.039 mmol), Pd(PPh3)4 (3 mmol%) and arylboronic 
acid  (1.0 equiv.) in THF (3 mL) was stirred at 55 °C for 10 h. under argon atmosphere. To the 
reaction mixture H2O (20 mL) and CH2Cl2 (25 mL) were added. The organic and the aqueous 
layers were separated and the latter was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuum .The 
residue was purified by column chromatography (silica gel, heptane/EtOAc).  
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7-(3,5-Methylphenyl)-4-oxo-3-phenyl-4H-chromen-5-yl trifluoromethanesulfonate (26a)  
Starting with 24 (20 mg, 0.039 mmol), 4a (6 mg, 0.039 
mmol), Pd(PPh3)4 (1.4 mg, 3 mole%), K3PO4 (8.2 mg, 0.039 
mmol), and THF (3 mL), 26a was isolated as a white solid 
(13 mg, 73%); mp 96-100 °C. 1H NMR (300 MHz, CDCl3): 
δ = 2.36 (s, 6H, 2CH3), 7.07 (s, 1H, ArH), 7.15 (s, 2H, ArH), 
7.32-7.40 (m, 4H, ArH), 7.47-7.51 (m, 2H, ArH), 7.64 (d, J 
= 1.7 Hz, 1H, ArH), 7.91 (s, 1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.10. 13C NMR 
(75.5 MHz, CDCl3): δ = 21.4 (2CH3), 116.6 (CH), 117.9 (C), 118.3 (q, JC,F = 320.8 Hz, CF3), 
125.1 (CH), 126.4 (C), 126.6, 126.7 (CH), 129.2 (2CH), 130.8 (C), 131.4 (CH), 137.2, 139.2, 
147.2, 147.5 (C), 152.2 (CH), 157.4 (C), 174.0 (CO). IR (KBr, cm-1): v = 3058, 3028, 2955 (w), 
2922 (m), 2852, 2733 (w), 1727 (m), 1650, 1623 (s), 1600 (m), 1545, 1487, 1444 (w), 1429 (s), 
1411 (w), 1400, 1375, 1365 (m), 1316, 1287, 1269 (w), 1247, 1225 (m), 1204, 1190 (s), 1159 
(m), 1141 (s), 1074, 1051 (w). GC-MS (EI, 70 eV): m/z (%) = 474 ([M]+,100), 409 (11), 382 
(10), 313 (34). HRMS (ESI/TOF) calcd. for C24H18O5F3S [M+H]
+: 475.08216; found: 
475.08218. 
 
7-(4-Ethylphenyl)-4-oxo-3-phenyl-4H-chromen-5-yl trifluoromethanesulfonate (26b)  
Starting with 24 (20 mg, 0.039 mmol), 4d (6 mg, 0.039 
mmol), Pd(PPh3)4 (1.4 mg, 3 mole%), K3PO4 (8.2 mg, 
0.039 mmol), and THF (3 mL), 26b was isolated as a 
white solid (15 mg, 79%); mp 99-101 °C. 1H NMR (300 
MHz, CDCl3): δ = 1.23 (t, J = 7.6 Hz, 3H, CH3), 2.67  (q, 
J = 7.6 Hz, 2H, CH2), 7.30 (d, J = 8.2 Hz, 2H, ArH), 7.33-7.38 (m, 4H, ArH), 7.47-7.50 (m, 
4H, ArH), 7.65 (d, J = 1.7 Hz, 1H, ArH), 7.91 (s, 1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ 
= -73.27. 13C NMR (75.5 MHz, CDCl3): δ = 15.4 (CH3), 29.7 (CH2), 115.2 (C), 116.3, 117.7 
(CH), 118.1 (q, JC,F = 321.3 Hz, CF3), 125.8 (C), 127.2 (CH), 128.6 (2CH), 129.0, 129.1 (CH), 
129.8, 133.5, 145.3, 145.8, 146.5, (C), 152.2 (CH), 156.5 (C), 172.3 (CO). IR (KBr, cm-1): v = 
3056, 3026 (w), 2959, 2922, 2851, 2817 (m), 1911, 1816, 1728, 1691 (w), 1646, 1626 (s), 1543, 
1521, 1494, 1461, 1446 (w), 1426 (s), 1401, 1376, 1367 (m), 1313, 1281 (w), 1256 (m), 1243, 
1208 (s). GC-MS (EI, 70 eV): m/z (%) = 474 ([M]+, 100), 342 (51), 326 (21), 313 (22). HRMS 
(EI, 70 eV) calcd. for C24H17O5F3S [M]
+: 474.07433; found: 474.07343. 
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7-(4-Methoxyphenyl)-4-oxo-3-phenyl-4H-chromen-5-yl trifluoromethanesulfonate (26c)  
Starting with 24 (20 mg, 0.039 mmol), 4e (6 mg, 0.039 
mmol), Pd(PPh3)4 (1.4 mg, 3 mole%), K3PO4 (8.2 mg, 
0.039 mmol), and THF (3 mL), 26c was isolated as a 
white solid (15 mg, 80%); mp 85-87 °C. 1H NMR (300 
MHz, CDCl3): δ = 3.82 (s, 3H, OCH3), 6.98 (d, J =8.6 Hz, 
2H, ArH), 7.33-7.37 (m, 4H, ArH), 7.48-7.53 (m, 4H, ArH), 7.61 (d, J = 1.7 Hz, 1H, ArH), 7.90 
(s, 1H, ArH). 19F NMR (282.4 MHz, CDCl3): δ = -73.28. 13C NMR (75.5 MHz, CDCl3): δ = 
55.5 (OCH3), 113.9, 114.7 (CH), 115.3 (C), 116.3 (CH), 117.9 (q, JC,F = 321.3 Hz, CF3), 125.7 
(C), 127.1, 128.5, 128.6 (CH), 129.8 (C), 131.0 (CH), 131.2, 145.4, 146.6 (C), 151.2 (CH), 
156.5, 160.0 (C), 172.9 (CO). IR (KBr, cm-1): v = 3072, 3057, 3020 (w), 2955, 2917, 2849 (m), 
1728 (m), 1650, 1627, 1601 (s), 1580, 1545 (w), 1519 (m), 1493, 1462 (w), 1427 (s), 1403, 
1373, 1364, 1292 (w), 1257, 1243, 1202, 1179, 1141, 1117 (s), 1071, 1043 (m). GC-MS (EI, 
70 eV): m/z (%) = 476 ([M]+, 100), 475 (18), 344 (44), 328 (20), 315 (18). HRMS (EI, 70 eV) 
calcd. for C23H15O6F3S [M]
+: 476.07433; found: 476.07343. 
 
7-(4-Methylphenyl)-4-oxo-3-phenyl-4H-chromen-5-yl trifluoromethanesulfonate (26d)  
Starting with 24 (20 mg, 0.039 mmol), 4f (5 mg, 0.039 
mmol), Pd(PPh3)4 (1.4 mg, 3 mole %), K3PO4 (8.2 mg, 0.039 
mmol), and THF (3 mL), 26d was isolated as a white solid 
(15 mg, 82%); mp101-102 °C. 1H NMR (300 MHz, CDCl3): 
δ = 2.37 (s, 3H, CH3), 7.26 (d, J = 7.9 Hz, 2H,  ArH), 7.33-
7.38 (m, 4H, ArH), 7.44-7.47 (m, 4H, ArH), 7.64 (d, J = 1.7 Hz, 1H, ArH), 7.90 (s, 1H, ArH). 
19F NMR (282.4 MHz, CDCl3): δ = -73.23. 13C NMR (75.5 MHz, CDCl3): δ = 21.2 (CH3), 
116.2 (CH), 116.6 (C), 117.7 (CH), 118.4 (q, JC,F = 320.8 Hz, CF3), 126.8 (C), 127.1 (CH), 
128.6 (2CH), 129.1, 130.2 (CH), 130.8, 134.3, 140.1, 146.8, 147.6 (C), 152.2 (CH), 157.5 (C), 
174.0 (CO). IR (KBr, cm-1): v = 3074, 2955, 2923, 2815, 1732 (w), 1640 (m), 1624 (s), 1575, 
1568, 1557, 1542, 1524, 1506, 1496, 1472, 1455, 1447 (w), 1424 (s), 1398, 1380, 1372 (m), 
1320, 1286, 1274 (w), 1256, 1244 (m), 1200, 1138 (s). GC-MS (EI, 70 eV): m/z (%) = 460 
([M)+, 100), 459 (54), 395 (13), 327 (16), 228 (12). HRMS (ESI/TOF) calcd. for C23H16O5F3S 
[M+H]+: 461.06651; found: 461.06672. 
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X-Ray Crystal Data 
Crystal data and structure refinement for 5e 
Identification code                         N1-Mono-4OMe  
Empirical formula C20H15F3O6S  
Formula weight 440.38  
Temperature 173 (2) K  
Wavelength 0.71073Å  
Crystal system monoclinic  
Space group (H.-M.) P 21/n  
Space group (Hall) -P 2yn  
Unit cell dimensions a = 8.1302(19) Å 
b = 5.3259(13) Å 
c = 42.899(10) Å 
α = 90.00 
β = 94.470(15) 
γ = 90.00 
Volume  1851.9(8) Å3  
Z 4  
Density (calculated) 1.580 Mg m−3  
Absorption coefficient 0.222 mm−1  
F(000) 904  
Crystal size 0.34 × 0.10 × 0.02 mm  
 range for data collection θ = 1.90- 24.30°  
Index ranges -9≤h≤9,-6≤k≤6, -48≤l≤49  
Reflections collected 15118  
Independent reflections 2952 [R(int) = 0.0672]  
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Completeness to  = 24.30° 97.8%  
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.9222 and 0.9952  
Refinement method Full-matrix least-squares on F2  
Data/ restraints / parameters 2952/0/ 273  
Goodness-of-fit on F2 1.016  
Final R indices [I>2σ(I)] R1 = 0.0450, wR2 = 0.0913  
R indices (all data) R1 = 0.0888, wR2 = 0.1075  
Largest diff. peak and hole 0.243 and - 0.406 e Å−3  
Crystal data and structure refinement for 11d 
Identification code                         N2-Mono-4OMe  
Empirical formula C19 H15 Br O3  
Formula weight 371.22  
Temperature 173 (2) K  
Wavelength 0.71073 Å  
Crystal system monoclinic  
Space group (H.-M.) C 2/c  
Space group (Hall) -C 2yc  
Unit cell dimensions a = 19.8135(6) Å 
b = 8.6733(2) Å 
c = 20.2861(5) Å 
α = 90.00 
β=112.5630(10) 
γ = 90.00 
Volume 3219.30 (15) Å  
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Z 8  
Density (calculated) 1.532 Mg m−3  
Absorption coefficient 2.566 mm−1  
F(000) 1504  
Crystal size 0.38 × 0.22 × 0.15 mm  
 range for data collection 2.98-32.50  
Index ranges -29≤h≤29,-12≤k≤13, -29≤l≤30  
Reflections collected 22818  
Independent reflections  5824[R(int) = 0.0256]  
Completeness to  = 32.50° 99.8%  
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.4422and 0.6995  
Refinement method Full-matrix least-squares on F2  
Data/ restraints / parameters 5824/0/210  
Goodness-of-fit on F2 1.011  
Final R indices [I>2σ(I)] R1 = 0.0313, wR2 = 0.0714  
R indices (all data) R1 = 0.0495, wR2 = 0.0775  
Largest diff. peak and hole 0.47 and −0.23 e Å−3  
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Crystal data and structure refinement for 16a 
Identification code                         K-Mono-3,5.Me  
Empirical formula C18H13F3O5S  
Formula weight 398.34  
Temperature 173 (2) K  
Wavelength 0.71073 Å  
Crystal system monoclinic  
Space group (H.-M.) P 21/c  
Space group (Hall) -P 2ybc  
Unit cell dimensions a = 15.7620(7) Å 
b = 7.7357(4) Å 
c =15.5226(6  Å 
α = 90.00 
β = 115.035(2) 
γ = 90.00 
Volume 1714.85(13)Å3  
Z 4  
Density (calculated) 1.543 Mg m−3  
Absorption coefficient 0.248 mm−1  
F(000) 816  
Crystal size 0.85× 0.37 × 0.02 mm  
 range for data collection θ = 2.63-29.06 
 
 
Index ranges -20≤h≤21,-10≤k≤10, -21≤l≤91  
Reflections collected 20048  
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Absorption correction Semi-empirical from equivalents  
 
Refinement method Full-matrix least-squares on F2  
Data/ restraints / parameters 4477/15/ 268  
Goodness-of-fit on F2 1.031  
Final R indices [I>2σ(I)] R1 = 0.0532, wR2 = 0.1182  
R indices (all data) R1 = 0.0983, wR2 = 0.1382  
Largest diff. peak and hole 0.268 and -0.384e Å−3 
 
 
Crystal data and structure refinement for 20c 
Identification code                         Chin-D-OMe  
Empirical formula C23 H19 N O2  
Formula weight 341.39  
Temperature 173 (2) K  
Wavelength 0.71073 Å  
Crystal system Monoclinic  
Space group (H.-M.) P 21/n  
Space group (Hall) -P 2yn  
Unit cell dimensions a = 21.2098(11) Å 
b = 5.9382(3) Å 
c =  26.9576(12) Å 
α = 90.00 
β = 93.634(3)° 
γ = 90.00 
Volume 3388.4(3) Å3  
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Z 8  
Density (calculated) 1.338 Mg m−3  
Absorption coefficient  0.085 mm−1  
F(000) 1440  
Crystal size 0.99 × 0.43 × 0.05 mm  
 range for data collection θ = 1.19- 19.00°  
Index ranges -28≤h≤27,-8≤k≤7, -36≤l≤36  
Reflections collected 45074  
Independent reflections 8958[R(int) = 0.0424]  
Completeness to  = 30.00° 99.7%  
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.9204 and 0.9958  
Refinement method Full-matrix least-squares on F2  
Data/ restraints / parameters 8958/0/475  
Goodness-of-fit on F2 1.003  
Final R indices [I>2σ(I)] R1 = 0.0489, wR2 = 0.1084  
R indices (all data) R1 = 0.1110, wR2 = 0.1410  
Largest diff. peak and hole 0.287 and -0.242 e Å−3  
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Crystal data and structure refinement for 26c 
Identification code                         Isoflavone-Mono-4OMe  
Empirical formula C23 H15 F3 O6 S  
Formula weight 476.41  
Temperature 173 (2) K  
Wavelength 0.71073 Å  
Crystal system monoclinic  
Space group (H.-M.) C 2/c  
Space group (Hall) C 2yc  
Unit cell dimensions a =  24.0109(9) Å 
b = 9.9045(4) Å 
c = 18.7132(8) Å 
α = 90° 
β =113.994(2)° 
γ = 90° 
Volume 4065.7(3) Å  
Z 8  
Density (calculated) 1.557 Mg m−3  
Absorption coefficient 0.227 mm−1  
F(000) 1952  
Crystal size 0.270 × 0.150 × 0.060 mm  
 range for data collection θ = 2.26- 22.86°  
Index ranges -33≤h≤33,-13≤k≤13, -25≤l≤25  
Reflections collected 25514  
Independent reflections 5704[R(int) = 0.0613]  
Completeness to  = 31.00° 99.8%  
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Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.9839 and 0.9125  
Refinement method Full-matrix least-squares on F2  
Data/ restraints / parameters 5704/0/299  
Goodness-of-fit on F2 1.092  
Final R indices [I>2σ(I)] R1 = 0.0460, wR2 = 0.1158  
R indices (all data) R1 = 0.0696, wR2 = 0.1251  
Largest diff. peak and hole 0.337and - 0.479e Å−3  
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                                                             Abbreviations 
 
              EtOAc                                    Ethylacetate 
              DMF                                      Dimethylformamide 
              DMSO                                   Dimethylsulfoxide 
              NEt3                                      Triethylamine 
              Tf2O                                      Trifluoromethanesulfonic Anhydride 
             THF                                        Tetrahydrofurane 
             DIPEA                                    Ethyldiisopropylamine 
             NMR                                       Nuclear Magnetic Resonance 
             HMQC                                    Heteronuclear Multiple Quantum Coherence 
             HMBC                                    Heteronuclear Multiple Bond Correlation 
             DEPT                                      Distortionless Enhancement by Polarisation Transfer 
             MS                                          Mass spectrometry 
             EI                                            Electronic Impact 
             ESI                                          Electrospray Ionization 
             HRMS                                     High Resolution Mass Spectroscopy  
            IR                                             Infrared Spectroscopy 
            Ar                                            Aromatic 
            Ph                                            Phenyl 
            TLC                                        Thin Layer Chromatography 
            HZ                                           Hertz       
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